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EXECUTIVE SUMMARY 
Background and aims 
In the United Kingdom, newborn screening for phenylketonuria (PKU) was 
introduced on a national level in 1969 and for congenital hypothyroidism (CHT) in 
1981. Recent developments in newborn blood spot screening in the UK, however, 
have highlighted the need to re-examine information and communication needs 
for parents and health professionals in this area.  These developments include: 
policy decisions in 2000 and 2001 to introduce screening for cystic fibrosis and 
sickle cell disorders respectively; innovations in screening technologies that have 
increased the number of disorders that can be detected from dried blood spot 
specimens; and raised expectations for informed consent. 
A recent systematic review of existing reviews on newborn blood spot screening 
and communication about screening revealed gaps in the research literature on 
communication for newborn screening.1  It also highlighted the lack of primary 
research on the information and communication needs of parents and health 
professionals in the newborn period. 
Research carried out by the Parent Support Research Team of the UK Newborn 
Screening Programme Centre has aimed to address some of the gaps in the 
literature.   A qualitative study was undertaken to assess parents’ and health 
professionals’ information needs.  In addition, the team carried out this survey of 
existing information resources on newborn blood spot screening for parents and 
health professionals, which is the focus of this report. 
The aims of the survey were to: 
• Identify existing information resources on newborn blood spot screening 
available to parents and health professionals internationally 
• Develop an appraisal tool to evaluate the quality of the existing information 
resources, with a view to identifying strengths and weaknesses of the available 
information 
• Draw on the survey of leaflets to inform the development of our own information 
resources: initially, a standardised pre-screening leaflet for parents throughout 
the UK. 
Methods 
Leaflets and other information resources on newborn blood spot screening were 
sourced through internet websites, health service providers and support 
organisations in the UK. 
Information resources on newborn blood spot screening and the conditions 
screened for were catalogued electronically for easy retrieval and analysis.  To 
identify leaflets that were relevant to the task of developing a general parent 
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leaflet, all leaflets that described the heel-prick test were included in the survey of 
leaflets.  Those that merely mentioned the procedure and/or contained 
information about the conditions only were excluded.   
An appraisal tool was developed by adapting DISCERN criteria for judging the 
quality of patient information on treatment choices, and National Screening 
Committee (NSC) criteria for making policy decisions about the implementation of 
screening programmes. Two researchers tested the tool by applying it to a limited 
number of leaflets, compared their answers and achieved agreement on what 
information was required to meet our criteria.  The finalised tool contained 
questions grouped under the following sub-headings: purpose of the leaflet; 
reasons for screening; process and consequences of screening; follow-up to 
screening; production of the leaflet. 
Findings 
Some of the key findings include: 
• Of the 106 leaflets included in the survey (see Appendix 5), most were for 
parents (79/106) and this was evident in the title of about half of them (42/79) 
and in the text of the great majority (67/79). 
• The vast majority of the leaflets (91/106) explained the aims of screening; 
three-quarters provided some information on the natural history of at least one 
of the conditions (79/106). Less than half of the leaflets (43/106), however, 
mentioned prevention or the difficulties of prevention. 
• The great majority of leaflets described the procedures for doing the blood spot 
screening test particularly how the blood sample is taken (93/106) and the 
possibility of repeat testing (76/106) 
• Two-thirds of leaflets (68/106) did not indicate whether or not screening was 
compulsory or mandatory, though many of these implied that screening was 
routine.  
• Less than half of the leaflets indicated when parents would receive screening 
results (45/106).   
• About half the leaflets contained information about the limitations or possible 
harms of screening (55/106). 
• The majority of leaflets indicated the need for follow-up tests to confirm 
diagnosis after a positive screening result (71/106).  
• The vast majority of leaflets cited no source of evidence for the information 
provided (89/106). 
• Over half the leaflets indicated the date of development and/or review (56/106), 
but the great majority (90/106) did not mention how the information was 
developed. 
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• Overall, the leaflets/information sheets rated better on issues rooted in 
DISCERN criteria for the provision of information on treatment choices, than on 
NSC criteria for choices regarding whether or not to introduce a screening 
programme.   
Conclusions 
Most leaflets provided information on their purpose, the aims of screening, the 
conditions screened for, the screening procedure, the need for follow-up to 
confirm positive screening results, and treatment for the conditions.  The 
appraisers, however, were generous when using the appraisal tool.  In some 
cases the information provided in the leaflets barely met the requirement.  Whilst 
most leaflets mentioned the benefits of screening, few addressed the issue of the 
possible harms, particularly false results, indicated that screening was a choice, 
discussed alternatives to screening, or gave information about when and how 
parents would receive results.  Fewer still provided any sources of evidence for 
the information provided or how the information was developed. 
Recommendations 
We recommend: 
• the use of DISCERN with topic specific guidelines as a starting point for 
developing patient information; 
• appraising patient information with DISCERN and a topic specific tool to access 
good practice in information provision. 
1. Background and aims 
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1.  BACKGROUND AND AIMS 
Newborn screening programmes are an important part of health care services 
because they enable early detection and treatment of certain disorders associated 
with significant morbidity or mortality.(1, 2) In the United Kingdom, newborn 
screening for phenylketonuria (PKU) was introduced on a national level in 1969 
and for congenital hypothyroidism (CHT) in 1981.  
Recent developments in newborn screening, however, have led to the need to re-
examine information and communication needs of parents and health 
professionals in this area. Policies to introduce newborn screening for sickle cell 
disorders and cystic fibrosis using the same Guthrie card blood sample were 
announced in 2000 and 2001 respectively. Innovations in DNA technologies and 
tandem mass spectrometry, which increase the number of disorders that can be 
detected from dried blood spot specimens, have introduced further complexity.  
Moreover, raised expectations for informed consent for treatment, screening, 
diagnosis, and research have led to the need to communicate clearly with parents 
about their child’s health and the choices that they face in relation to testing and 
its possible consequences. Furthermore, with the expansion of screening services 
to include cystic fibrosis and sickle cell disorders, research is needed to 
understand how to provide parents and health professionals with information 
relevant to all four conditions. 
Our plan, therefore, was to develop and pilot information resources for parents 
and health professionals and communication guidelines for health professionals.  
Three separate but related pieces of work have informed this process.  
First, a systematic review of existing reviews on newborn blood spot screening 
and on communication about screening commissioned by the Cochrane 
Collaboration and the NHS Health Technology Assessment programme revealed 
gaps in the research literature on communication for newborn screening.(3) Most 
striking is the lack of primary research that considers the information and 
communication needs of parents and health professionals in the newborn period.  
The review also highlighted the need for good-quality standardised information 
resources about screening. 
Second, focus groups and interviews with parents and health professionals have 
also helped us identify information needs of these groups.   
Finally, to draw on the strengths of existing materials, we carried out an 
international survey of information resources (leaflets and information sheets) 
currently available through the internet and health service providers. This work is 
reported here, and the implications considered for the development of a leaflet on 
newborn blood spot screening and other information resources available to both 
parents and health professionals.  This work is also reported in a paper in a peer-
reviewed journal.2  
The aims of the survey were to: 
• Identify existing information resources on newborn blood spot screening 
available to parents and health professionals internationally 
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• Develop an appraisal tool to evaluate the quality of the existing information 
resources, with a view to identifying strengths and weaknesses of the available 
information 
• Draw on the survey of leaflets to inform the development of our own information 
resources: initially, a standardised pre-screening leaflet for parents throughout 
the UK. 
2. Methods 
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2. METHODS 
Outline of Chapter 
This chapter describes the methods used in the survey: namely, identification of 
leaflets and www pages, development of the survey instrument, and the methods 
of analysing the data. 
2.1 Research question and inclusion criteria 
We sought to answer the research question:  what written information is publicly 
available about routine newborn blood spot screening for phenylketonuria, 
congenital hypothyroidism, cystic fibrosis and sickle cell disorders? The purpose 
of identifying these documents was to inform the development of a pre-screening 
leaflet by building on existing materials.  Documents to be included needed to:  
i. DESCRIBE newborn blood spot screening (i.e. included reference to taking 
blood from the baby’s heel for screening tests) or, as it is sometimes known, 
the heel-prick or the Guthrie test. 
Documents were to be excluded if they: 
ii. MENTIONED newborn screening but did not include information about testing 
blood taken from the baby’s heel; or 
iii. referred to one or more of the four conditions screened for but contained NO 
information on newborn screening itself. 
2.2 Searching for information on newborn blood 
spot screening 
Leaflets and information sheets on newborn blood spot screening were sought 
through  
• Internet websites  
• Health service providers 
• Support organisations  
2.2.1 Internet websites 
The following categories of website were searched using the Google search 
engine: 
i. Children’s hospitals in the UK, USA, Canada and Australia. These were 
selected as leading providers of health care for children affected by the 
screened conditions; 
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ii. Support organisations and charities in the UK (see Section 1.3); 
iii. Links provided on the above websites to specialist websites with information 
on newborn blood spot screening and/or the particular conditions; 
iv. Professional bodies and health organisations (e.g. Department of Health, 
National Health Service (NHS), American Association of Paediatricians 
(AAP)). 
Sections on the websites referring to patient/consumer/parent information or 
health professional information were searched to identify information on newborn 
blood spot screening generally, and information or fact sheets on the specific 
conditions phenylketonuria (PKU), congenital hypothyroidsim (CHT) cystic fibrosis 
(CF) and sickle cell disorders (SC). 
The search facility for each website was used to search for the following words 
and phrases: 
i. ‘newborn screening’ 
ii. ‘newborn screening program(me)’ 
iii. ‘neonatal screening’ 
iv. ‘in-born errors of metabolism’ 
v. ‘phenylketonuria’ and ‘PKU’ 
vi. ‘hypothyroidism’ 
vii. ‘cystic fibrosis’ 
viii. ‘sickle cell’ 
Many websites did not appear to contain any information on newborn blood spot 
screening.  Each site was searched thoroughly before it was determined that no 
relevant information could be found on the site.  All relevant leaflets/information 
sheets found on the internet were printed out and catalogued. 
2.2.2 Health service providers 
Leaflets and information sheets were sought from health service providers, 
including all laboratories screening for sickle cell disorders and cystic fibrosis in 
England and Wales, specialists other individuals involved in wider Programme 
Centre networks such as sickle cell counsellors, cystic fibrosis nurses, midwives, 
and screening programme co-ordinators.  Leaflets and information sheets were 
also provided by the Sickle Cell and Thalassaemia Screening Programme who 
undertook a scoping exercise to determine the range of resources available to 
parents on newborn blood spot screening.(4) 
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2.2.3 Support organisations 
We contacted the following support organisations for leaflets on newborn 
screening and the four conditions to be screened for nationally: 
• Cystic Fibrosis Trust (CF Trust) 
• Sickle Cell Society 
• British Thyroid Foundation 
• National Society for Phenylketonuria (NSPKU) 
• Contact a Family 
• Children Living with Inherited Metabolic Diseases (Climb)  
• National Childbirth Trust (NCT) 
2.3 Cataloguing leaflets and information sheets 
All leaflets on newborn screening and/or the four conditions were numbered, to 
facilitate accurate retrieval and analysis, and catalogued on a Reference Manager 
database with their citation details.  They were coded for: the condition being 
screened (PKU, CHT, SCD, CF, or a general leaflet on newborn blood spot 
screening); their target audience  (e.g. parent, health professional); and country of 
origin (e.g. UK, USA, AUS, etc.). 
2.4 Identifying relevant leaflets 
One researcher conducted the search and was over inclusive in applying the 
inclusion criteria. Two researchers independently applied the inclusion criteria to 
all documents initially identified. Discrepancies were resolved through discussion. 
2.5 Developing an appraisal tool 
We drafted an appraisal tool to evaluate the leaflets. We drew on two existing sets 
of criteria: the DISCERN instrument, which was developed to evaluate the quality 
of consumer health information on treatment choices (see Appendix 1),(5) and the 
NSC criteria for determining the appropriateness of potential screening 
programmes (see Appendix 2).(6) 
Whilst the intervention(s) considered by DISCERN involves treatment, the 
intervention for the NSC is screening itself. To draw together these criteria they 
were first grouped into the following themes: 
• The conditions (treated / screened for) 
• Different options 
• Decision-making  
2. Methods 
Survey of information resources on newborn blood spot screening for parents and health 
professionals 9 
• The intervention process 
• What happens next 
• The effectiveness of the intervention  
Grouping the criteria in this way, enabled cross cutting issues to be identified, and 
a set of synthesised criteria drafted that took into account DISCERN’s focus on 
high quality information for treatment choices and the NSC’s focus on screening. 
Whilst not all DISCERN or NSC criteria were appropriate for inclusion in a tool for 
appraising parent information on newborn screening, most of these criteria could 
be adapted to the screening context. 
To refine the tool, two researchers independently applied the questions to four 
separate leaflets/web pages on newborn blood spot screening.  Responses to the 
questions were compared and discussed between the two researchers; where 
necessary the questions were clarified in order to achieve more consistent 
responses. The refined appraisal tool was applied to ten more leaflets/web pages 
and then a further five for a total of three rounds of comparing independent 
appraisals and refining the tool as necessary. The resulting appraisal tool focused 
on five criteria for assessment of content comprising purpose of leaflet, reasons 
for screening, process and consequences of screening, follow-up to screening, 
and production of the leaflet. The appraisal tool is attached as Appendix 3. 
The finalised questions included in the appraisal tool were organised into 
subheadings to prepare a template for high-quality newborn screening information 
for parents and health professionals (see Box 1). 
2. Methods 
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Box 1: Issues addressed when appraising leaflets 
 
Purpose of Leaflet 
Is it clear whom it is for? 
If so, how is this indicated in the leaflet? 
Is it clear when the information would be given? 
 
Reasons for Screening 
Aims/reasons for screening 
Natural history of the conditions screened for 
Prevention programmes/difficulties of prevention 
 
Process and Consequences of Screening 
Description of the heel-prick test 
Indication of when parents will receive results 
Information on whether screening is not compulsory or mandatory 
The limitations of screening (e.g. false-negative, false-positive results) 
Costs of screening 
Cost-effectiveness of screening 
 
Follow-up to Screening 
Information on need for further testing for diagnosis 
Treatment for the conditions screened for 
Any related services 
 
Information about Carriers 
Babies may be identified as carriers 
Babies’ DNA may be tested 
Mutations tested for 
Implications of carrier status for babies’ health 
Parents may be identified as carriers 
Wider implications for families 
 
Production of the Leaflet 
Sources of evidence  
Is specific information linked to evidence? 
Level of complexity of the leaflet 
Indication of how the leaflet was developed 
2.6 Appraising the leaflets 
Having finalised the set of questions, the appraisal tool was then entered into 
specialist software (EPPI Reviewer) and used to evaluate each individual leaflet.  
Some minor modifications were made to the set of questions at this stage as we 
gained a greater understanding of the leaflets. Two researchers independently 
evaluated each leaflet.  Discrepancies were discussed and resolved. 
3. Results: appraisal of leaflets 
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3. RESULTS: APPRAISAL OF LEAFLETS 
Outline of Chapter 
This chapter describes the findings of the survey: namely, how well the leaflets 
and information sheets reported their purpose, the reasons for screening, the 
process and consequences of screening, follow-up care, and how the leaflet was 
produced. 
Key findings 
Purpose of the leaflet 
• Most leaflets were for parents (79/106) and this was evident in the title of about 
half of them (42/79) and in the text of the great majority (67/79). 
• About half of the leaflets (50/106) were developed to provide information prior 
to screening. 
Reasons for screening 
• The vast majority of the leaflets (91/106) explained the aims of screening 
generally, for a specific population, or both.  The 15 leaflets that did not contain 
this information, were guidelines for health professionals or condition-specific 
leaflets, rather than general information resources for parents. 
• Three-quarters of the leaflets provided some information on the natural history 
of at least one of the conditions (79/106).  
• Less than half of the leaflets (43/106) mentioned prevention or the difficulties of 
prevention; almost all of these mentioned whether or not the conditions were 
inherited (39/43), and some mentioned reproductive choice or other means of 
prevention (11/43). 
Process of screening 
• The great majority of leaflets describe the procedures for doing the blood spot 
screening test particularly how the blood sample is taken (93/106), the 
possibility of repeat testing (76/106), what happens to the card once the blood 
spots are taken (72/106). Few leaflets indicate that the test will be 
uncomfortable for the baby (19) or how the pain might be eased (5). 
• Two-thirds of leaflets (68/106) did not indicate whether or not screening was 
compulsory or mandatory, though many of these implied that screening was 
routine.  A quarter of the leaflets state that screening is not compulsory 
(25/106), but several of these also emphasise the importance of screening by 
recommending screening (10) or outlining the implications of not screening (4). 
• All 16/106 leaflets stating that screening is mandatory were from the United 
States where it is mandated by law. 
Consequences of screening 
• Less than half of the leaflets indicated when parents would receive screening 
results (45/106).  Less than half of these mentioned both negative and positive 
results (17/45). 
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• Less than a quarter of the leaflets contained information about the limitations or 
possible harms of screening in terms of the risk of false negative (15/106) or 
false positive results (22/106).  More leaflets, however, mentioned other 
possible harms such as anxiety associated with the need for repeat tests 
(41/106).   
• Few of the leaflets mentioned the costs of screening (14/106) and fewer still the 
cost-effectiveness (5/106).  Those mentioning costs or cost-effectiveness were 
almost all from the United States. 
Follow-up to screening 
• The majority of leaflets indicated the need for follow-up tests to confirm 
diagnosis after a positive screening result (71/106).  Almost all of these (69/71) 
informed about the circumstances in which follow-up would occur, but few 
leaflets indicated when parents would be told about the need for follow-up tests 
(9), when such tests might occur (12), or when parents would receive results of 
follow-up tests (1). 
• Most leaflets mentioned treatment for at least one of the four conditions 
(73/106) and almost all of those mentioning treatment also gave some 
information about the natural history of the conditions. 
• Of the 66 leaflets that referred to a service related to newborn screening, the 
majority (48/66) referred to health professionals or specialists, and over a third 
referred to support organisations (23/66). 
Information about Carriers 
• Almost half of the leaflets (49/106) referred to carriers.  About half of these 
(23/49) indicated that, as an outcome of screening, babies may be identified as 
carriers of the conditions screened for, or that parents might be carriers (24/49). 
Production of the leaflet 
• The vast majority of leaflets cited no source of evidence for the information 
provided (89/106).  Seventeen of the leaflets included reference to policy 
documents, research papers or named specialist reviewers. 
• Over half the leaflets indicated the date of development and/or review (56/106), 
but the great majority (90/106) did not discuss how the information was 
developed. 
• Over half the leaflets were appraised as ‘easy to read’ (56/106); about a third 
contained technical terms that were unexplained (36/106) and 14 leaflets 
required some expert knowledge to understand. 
Over 300 leaflets were found in our initial search for information sheets/leaflets on 
newborn blood spot screening.  106 leaflets met our inclusion criteria of 
describing newborn blood spot screening:  thirty-four from the USA (33%), 68 
from the UK (64%) and four from Australia (4%).   
The results of the survey are set out below in three sub-sections.  The first reports 
the results from applying our appraisal tool, the second and third sections report 
how well the leaflets matched DISCERN and NSC criteria respectively.   
3. Results: appraisal of leaflets 
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The questions selected for inclusion in our appraisal tool were grouped under the 
following sub-headings: the purpose of the leaflet; reasons for screening; process 
of screening; consequences of screening; follow-up to screening, and the 
production of the leaflet. 
3.1. Purpose of the leaflet 
The purpose of each leaflet was considered in terms of who it was for and for 
when it was provided. 
Seventy-nine (75%) of the 106 leaflets clearly indicated that they were intended to 
provide information for parents or carers of babies.  Nineteen of the leaflets 
indicated that they were specifically written for health professionals.  One leaflet 
was intended for both parents and health professionals, one was for parents and 
wider family members and one was for parents and adults more generally.  For 
eight of the leaflets, the intended audience was not clearly specified (see Table 
1.1). 
Table 1.1: Is it clear whom the leaflet is for?* 
Target audience Number 
Parent/carer 79 
Families 1 
Adults 2 
Health professionals 19 
Not clear for whom leaflet intended 8 
Total number of leaflets 106 
* Some documents appear in more than one category 
We then looked at whether the intended audience was indicated in the title of the 
leaflet or in the text.  Of the 98/106 leaflets that were clear about the intended 
audience, this was more likely to be indicated in the text (82/98) than in the title of 
the leaflet (45/98). In over a third of the leaflets clear about their intended 
audience (36/98) this was indicated in both the title and the text.  Most leaflets 
were for parents (79/106) and this was evident in the title of over half (42/79) and 
the text of four-fifths of the leaflets (67/79). To be indicated in the text, the leaflet 
needed to contain phrases such as ‘your baby’ or ‘my baby’.  Illustrating this point, 
some leaflets intended for parents provided information by posing and answering 
questions commonly asked by parents about screening, for example,  
“Q1. Did I do something wrong in my pregnancy which resulted in my baby 
having congenital hypothyroidism?” “A. The answer is most certainly NO” 
[128].* 
In 45/106 leaflets it was not clear at what stage in the screening pathway the 
leaflet was to be given.  In 50, it was clear that the information was to be given 
before screening took place (antenatally or postnatally).  Three of these 50 
leaflets were also given as part of a consent process by screening programmes in 
                                                
* A list of numbered leaflets included in this survey is attached as Appendix 1. 
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the USA that were carrying out pilot research for supplemental screening 
programmes, and one was part of a consent process for newborn screening in 
Scotland.  The majority of the leaflets to be given before screening took place also 
described how the blood sample was taken from the baby’s heel (45/50).  39/50 
discussed the possibility of a repeat screening test, and 32/50 described how 
results were reported to parents.   
Other leaflets provided information on conditions which was clearly to be given to 
parents with positive screening results (8/106), after a confirmed positive 
diagnosis (2/106), or with a request for a repeat blood sample (1/106). 
Table 1.2: Is it clear from the leaflet when in the screening pathway this 
information would be given?* 
Timing of information giving Number 
Yes, Before screening takes place (antenatally or postnatally) 50 
Yes, As part of the consent process 4 
Yes, With screening results 8 
Yes, After confirmed positive diagnosis 2 
Yes, at other time (e.g. when repeat blood sample requested) 1 
No 45 
Total number of leaflets 106 
* Some documents appear in more than one category 
3.2 Reasons for screening 
Over four-fifths of the leaflets (91/106) explained the aims or reasons for 
screening (see Table 1.3).  Researchers noted that during the appraisal process, 
however, reasons were often implied rather than the aims of screening being 
explicit.  Fifteen of the 106 leaflets gave no reasons for screening.   These 
included leaflets describing screening protocols for health professionals, or 
providing information on a specific condition screened for rather than newborn 
screening generally (e.g. ‘Information for parents/carers for cystic fibrosis’ [46], 
‘Hypothyroidism and your infant’ [160]).  Others gave results information to 
parents whose babies received a positive screening result.  One US leaflet for 
health professionals provided bullet-point information to be passed on to patients 
about ensuring that newborn babies were screened before leaving hospital.    
Eighty-eight out of the 106 leaflets explained why screening tests were 
recommended.  Twenty-four explained the importance of screening a particular 
population, often providing statistics about the frequency of occurrence of one or 
more of the disorders in that population.  For example, one leaflet for parents 
describes PKU as a “rare disorder that affects 1 in every 8,000 babies born in 
Scotland” [268].  Twenty-one of the 106 leaflets explained both the reasons for 
screening generally and the importance of screening a particular population for a 
certain disorder. 
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Table 1.3: Does the leaflet give the aims of/reasons for screening?* 
Aims of screening Number 
Yes, Explains why the tests are recommended/important  
(list conditions covered) 88 
Yes, Explains importance to screen a particular population 
(list conditions covered) 24 
No 15 
Total number of leaflets 106 
* Some documents appear in more than one category 
Seventy-nine leaflets (75%) provided some information on the natural history of at 
least one of the conditions; 27 did not provide information about any of the four 
conditions, though one of these provided internet hyperlinks for condition-specific 
information.  The conditions most likely to be described were CHT (62/106) and 
PKU (58/106).  About a quarter of the leaflets described sickle cell disorders 
(29/106) or cystic fibrosis (27/106), and 22 described other conditions. 
We were interested in the extent to which leaflets explained the importance of 
screening for these conditions and the lack of other prevention programmes.  
Over half the leaflets (63/106) made no mention of whether or not these 
conditions could be prevented or the difficulties of prevention.  Of the 43/106 
leaflets that did mention prevention or difficulties of prevention of the conditions, 
most (39/43) mentioned whether or not the disorders were inherited.  A few 
mentioned preconception and/or antenatal screening or reproductive choice 
(7/43) as methods of prevention, provided other information about prevention 
programmes (3/43) or indicated that, apart from reproductive choice, no 
prevention programmes existed (1/43). 
Table 1.5: Does the leaflet discuss available prevention programmes and/or the 
difficulties of prevention?* 
Prevention/difficulties of prevention Number 
Yes, Indicates whether or not disorders are inherited 39 
Yes, Mentions preconception and/or antenatal screening and 
reproductive choice 7 
Yes, Provides other information about prevention programmes 3 
Yes, Specifies that apart from reproductive choice, no prevention 
programmes exist 1 
No 63 
Number of leaflets 106 
* Some documents appear in more than one category 
3.3 Process of screening 
We examined in detail the amount of information provided in each leaflet about 
the actual screening process.  Given our initial selection criteria to include only 
leaflets that described some aspect of the screening test, most of the leaflets 
described how the blood sample was taken from the heel (93/106).  Less than a 
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fifth, however, indicated that this might be uncomfortable for the baby (19/106); 
and few suggested how the pain might be eased (5/109).  Leaflets that mentioned 
discomfort for the baby were produced in the UK for parents: 7/19 since 2000, 
though the rest were undated. Statements about discomfort tended to minimise 
the significance of the baby’s pain in relation to the potentially significant health 
benefits of screening.  For example, they contained statements such as:  
It will only cause a moment of discomfort, which your baby will soon forget.  
The heel-prick mark will disappear in a few days [195];  
and  
Most babies cry a bit when the heel is pricked but the discomfort is only for 
a moment and the possible benefits are for a lifetime [194].   
Over half of the leaflets (57/106) explained how the blood spots were placed on 
the Guthrie card.  Seventy-two leaflets described what happened next to the 
blood sample, and 76 of the 106 leaflets discussed the possibility of a repeated 
screening test.  About half (54/106), described how results were reported to 
health professionals and then made available to parents.  Few leaflets discussed 
the storage or later use of the blood spots (3/106).  Thirteen leaflets addressed 
other issues related to performing the heel-prick test, such as the existence of 
registers and the option to opt out of research on blood spots (1); the risks 
associated with puncturing the heel (1); protocols for health professionals to follow 
(5); anonymous HIV testing (2) quality assurance mechanisms (1); repeat blood 
tests to rule out thalassaemia in older children (1); genetic tests for cystic fibrosis 
(1); and testing parents in cases of suspected haemoglobinopathy (1). 
Table 1.6: Does the leaflet describe the procedures for doing the heel-prick test?* 
Information about heel-prick test Number 
Yes, Describes how the blood sample is taken 93 
Yes, Indicates that it may be uncomfortable for the baby 19 
Yes, Describes how pain may be eased for baby 5 
Yes, Describes how blood spots placed on the Guthrie card 57 
Yes, Describes what happens next to the card/blood sample 72 
Yes, Describes how results are reported 54 
Yes, Discusses the possibility of a repeated test 76 
Yes, Indicates storage/possible later use of cards 3 
Yes, Other (please specify) 13 
No 3 
Total number of leaflets  106 
* Some documents appear in more than one category 
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3.4 Consequences of screening 
Screening programmes have immediate consequences in terms of offering (or 
withholding) choice to parents, reporting results of screening, and the costs of 
screening. 
More than half of the leaflets (61/106) gave no information about when parents 
would receive or be asked to collect screening results.   Of the 45 that indicated 
when parents would receive results, 17 specified this for both positive and 
negative results.  
With the increased focus on informed choice for treatments and screening, we 
were interested to find out whether leaflets indicated that parents could choose 
whether or not their baby was screened.   The situation differs in the USA where 
newborn screening is mandated by law.  In this context, we were interested in 
how US leaflets addressed the issue that screening is compulsory.  Our analysis 
showed that almost two-thirds of the leaflets (68/106) did not state directly 
whether or not screening was compulsory.  Many leaflets implied, however, that 
screening all babies took place as a matter of course.  Illustrating this point, one 
US leaflet states:   
While your newborn baby is in the hospital or shortly afterward, he or she 
will have a blood sample taken to screen for certain birth defects [36]. 
Similarly, a UK leaflet begins:  
The heel prick test is carried out on all babies born in the UK at 6 days of 
age. [303] 
Leaflets specifying that screening was not obligatory (25/106) provided varied 
information around the concept of ‘choice’.  Some leaflets presented screening as 
a choice but also emphasised the importance of screening by recommending it 
(10) or outlining the implications of not screening (4).  For example, one UK leaflet 
for parents stipulates that:   
All babies born in Scotland are eligible….  It is important that you realise 
that a delayed diagnosis of any of the conditions below may lead to 
permanent damage to your baby” [268].   
Similarly, another UK leaflet informs parents that  
In this country the newborn screening test is not a legal requirement (unless 
a baby is up for adoption) but it is very important, since a delayed diagnosis 
may cause your baby permanent damage” [194]. 
Twelve leaflets that indicated that screening was not compulsory outlined the 
processes of accepting or refusing screening for a baby.  Some of these leaflets 
indicated that refusal might have negative consequences for newborns.  For 
example, an Australian leaflet informed that:  “Parents may refuse the newborn 
screening test on behalf of their baby. However the programme diagnoses 70-80 
babies each year for whom treatment is urgently needed, and refusal of the test 
might unnecessarily risk the baby’s health” [43].  Two UK leaflets took a more 
neutral position:  one leaflet for parents commented that  “If you do not want these 
screening tests to be undertaken your wishes will be respected” [107]; and 
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another, for health professionals, merely outlined the recording protocol for 
refusals.  Three of these 12 leaflets stated that screening was optional only in the 
context of pilot screening programmes in the USA. 
Understandably, because of its legal position, all the leaflets/sheets stating that 
newborn blood spot screening was mandatory (16/106) were from the USA.  Six 
of these leaflets stipulated the reasons for refusal of the tests. One leaflet 
informed parents that:  
In Massachusetts you may refuse for religious reasons.  If you do so, you 
may be asked to sign a refusal form.  This form relieves your doctor of any 
liability for damages that result from a disorder that could have been 
detected by screening [157].   
Another US leaflet indicated that people could also refuse: 
in many states, because of their personal beliefs [12].   
Neither leaflet explains what constitutes ‘religious beliefs’ or ‘personal beliefs’. 
About half of the leaflets (55/106) discussed the limitations or possible harms of 
screening, which meant that a significant proportion of the leaflets did not address 
these issues.  Over half of the leaflets written for parents (43/79), and half of 
those intended health professionals (8/19) contained this information, including 
the risk of false-negative (19/55), or false-positive (22/55) results.  Forty-one of 
the 55 leaflets that addressed the limitations of screening discussed other 
possible harms such as parental anxiety associated with the need for repeated 
tests because of insufficient blood or unclear results. 
The issue of the costs of screening was not addressed in most of the leaflets 
(92/106). Those including information on costs were almost all from the USA, and 
mentioned costs to parents (12/14), health care services (7/14) or health insurers 
(5/14).  Very few leaflets addressed the issue of the cost-effectiveness of 
screening (5/106). 
3.5 Follow-up to screening 
The need for further testing to confirm a diagnosis after a positive screening result 
was mentioned in the majority of the leaflets (71/106).  Almost all of these leaflets 
(69/71) identified the circumstances in which follow-up would occur.  For example, 
one UK leaflets states that:  “In the unlikely event that a test is abnormal there will 
be no delay in arranging through your family doctor for your baby to be seen by a 
paediatrician” [106].  Few leaflets, however, contained any information about 
when parents would hear about the necessity for follow-up tests (9/106), when 
such tests might occur (12/106), and only one indicated when parents would 
receive the results of any follow-up tests. 
Treatment for any of the four conditions screened for was mentioned in most of 
the leaflets (73/106).  Almost all leaflets that mentioned treatment for PKU also 
mentioned the natural history of the condition (52/59).  Similarly, 53 of the 58 
leaflets that mentioned treatment for CHT and 16 of the 18 leaflets mentioning 
treatment for sickle cell disorders also discussed the natural history of the 
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condition. All of the leaflets mentioning treatment for CF (15/15) also discussed 
the natural history of the condition.   
Sixty-six of the leaflets referred to some form of service related to newborn 
screening.  This was primarily to health professionals or specialists (48/66).  Other 
related services indicated in leaflets were support organisations within the health 
service or charities (23/66), counselling, including genetic counselling (16/66) and 
other services such as supplementary screening programmes (16/66). 
3.6 Information about Carriers 
Almost half of the leaflets (49/106) referred to carriers.  About half of these (23/49) 
indicated that, as an outcome of screening, babies may be identified as carriers of 
cystic fibrosis (10), sickle cell disorders (9), PKU (2) or other disorders (3). Twelve 
leaflets mentioned that babies’ DNA might be tested, and 19 mentioned the 
implications of carrier status for babies’ health.  Almost half of the leaflets 
mentioning carriers (24/49) indicated that parents might be carriers of sickle cell 
disorders (10), PKU (9), cystic fibrosis (8) or other disorders (4). The following 
information relating to carrier status also appeared in some of the leaflets:  the 
implications of being a carrier for family planning and reproductive choice (19); 
wider carrier testing for family members (10); uncertainty regarding diagnosis (8); 
the number of carriers in the population (8); the psychological implications (e.g. 
anxiety) (6); not all mutations are tested for (4); and the number of mutations 
being tested (3). 
3.7 Production of the leaflet 
Over four-fifths of the leaflets (89/106) contained no sources of evidence for the 
information provided.   Sources of evidence we were looking for included 
reference to policy documents, research papers or the names of specialist 
reviewers.  Seventeen of the leaflets cited any of these types of evidence.  About 
half of these were produced in the USA, primarily as public or health professional 
educational materials (8/16). 9/16 leaflets were produced in the UK, and included: 
health professional guidelines (4), a leaflet for parents including technical details 
of screening for CF (1) leaflets for parents whose babies have received a positive 
screening result (2), or needed a repeat test (1), a commercially-sponsored leaflet 
on newborn screening (1), and a booklet on thyroid disorders (1).  Only four of the 
17 leaflets gave dates for the evidence provided.  One of these was a summary 
for health professionals produced in the UK, appearing on a website and 
providing a list of additional reading resources and a glossary of terms related to 
screening, rather than a list of references per se.  Six of the 17 leaflets providing 
evidence indicated using more than one type of source in its development.  This 
included one information resource produced by an on-line medical encyclopaedia 
[209]. 
Two of the 106 leaflets appraised gave information linked to the evidence.  One 
North American leaflet reported case studies of babies whose conditions were not 
picked up by routine newborn screening but might have done had their parents 
chosen supplemental screening for their baby.  The other leaflet referred to UK 
Department of Health guidelines for good practice. 
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Over half (56/106) of the leaflets indicated the date when it was developed and/or 
updated, but the great majority (90/106) did not indicate how the information was 
developed.  All but one leaflet providing this information (16/106) indicated that 
the leaflet was developed through clinical specialist knowledge or collaboration 
between specialists and committees of experts. One UK leaflet stated that the 
leaflet was produced taking into account the views of parents. 
In terms of the complexity of the leaflets and the ease of reading them, over half 
(56/106) were appraised as easy to read, with technical terms explained or stated 
in lay language.  About a third (36/106) included technical terms that were 
unexplained or confusing, and 14 required expert or medical knowledge to 
understand.  Forty-nine of the 79 leaflets designed for parents were easy to read, 
with many carefully explaining technical terms in lay language.  Four of the 19 
leaflets for health professionals were easy to read.  Of the 14/106 leaflets that 
required medical expertise to understand, 10 were for health professionals, two 
appeared to be for parents/carers, and for two the target audience was unclear.  
Two parent leaflets were appraised as requiring expert knowledge to understand.  
For example, one of these leaflets explained that:   
Expanded newborn screening using tandem mass spectrometry (TMS) 
commences in 2002.  TMS detects changed levels of metabolites in the 
blood spot, which may indicate disorders of metabolism of fatty acids and 
amino acids [41].   
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4. RESULTS: APPLYING STANDARDS FOR 
PERSONAL DECISIONS 
Outline of Chapter 
This chapter considers the challenge of encapsulating standards for evidence-
based treatment choice in information for screening. It reflects on the process of 
interpreting and applying appraisal criteria, and discusses how well screening 
information appears to reflect the principles underpinning the DISCERN 
instrument that address the reliability of the publication to inform decisions (is the 
purpose clear, the information relevant and up-to-date, and is how it was prepared 
reported?) and the quality of information provided (balanced and unbiased, 
acknowledging uncertainty, referring to sources of additional information, support 
and research evidence). 
Key findings 
Interpreting evidence-informed treatment choice for patients for screening 
decisions: 
• Translating DISCERN criteria into a tool for discriminating information relatively 
more able to support evidence-informed parent choice required us to be 
generous in making judgements 
Most leaflets reflected the following principles expressed by DISCERN: 
• The aims are clear, including what the publication is about and who is the 
intended audience 
• The publication is relevant to the intended audience 
• The information describes why babies are screened and the importance of 
early detection 
Less than half of the leaflets reflected the following principles expressed by 
DISCERN: 
• Sources and dates of evidence are given for the information provided 
• Additional sources of support and information appear in the publication 
• The importance of screening a specific population is mentioned 
• The information describes the limitations and uncertainties of screening as well 
as the benefits 
• Screening is presented as a choice or mandatory; alternatives to screening to 
screening are described 
• Information about support for shared decision-making is provided. 
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4.1 Standards for personal decisions 
4.1.1 Applying DISCERN criteria  
The DISCERN criteria address the reliability of the publication to inform decisions 
and the quality of information provided. The instrument asks: is the purpose clear, 
the information relevant and up-to-date, and is how it was prepared reported? It 
asks is the information provided balanced and unbiased; does it acknowledge 
uncertainty, and refer to sources of additional information, support and research 
evidence? 
The details for how we did this is recorded in appendix 5 where we match the 
DISCERN criteria to acceptable answers from our tool that would indicate meeting 
those criteria. In order to discriminate between screening information that might 
provide any evidence to support parent choice, and screening information that did 
not, we applied a low threshold when applying these criteria. For instance, in 
considering whether the information was balanced and unbiased, we accepted 
mere mention of false positive AND false negative results OR other harms, such 
as the anxiety that parents may experience when newborns undergo blood spot 
screening. We did not appraise the quality of the explanations of these concepts. 
For this reason, our analysis of how well screening leaflets meet DISCERN 
criteria for quality of patient information must be considered to be a description of 
minimum requirements rather than what might be accepted as good practice. 
4.1.2 Reliability of the publication 
To support informed choices about screening, leaflets need to be explicit in their 
purpose of informing parents prior to screening. We found that 58/79 (73%) of the 
leaflets for parents were clear about when the information should be provided.  
We judged whether leaflets were explicitly relevant to parents facing screening if 
they contained information about the importance of newborn screening generally 
and for a specific population.  We found that 91/106 of the leaflets provided 
information on the importance of newborn screening generally or the importance 
of screening a particular population, but only 21/106 (20%) provided information 
on both. Eleven of the latter were from the UK, nine from the USA and one from 
Australia. 
Only four of the 106 leaflets provided evidence to support the information 
provided and the dates of the publication of this evidence.  Three were from the 
US and one from the UK.  Two were public health education information sheets 
and two were fact sheets or reference materials for health professionals. 
4.1.3 Quality of the information 
We judged that leaflets were balanced, unbiased and open about areas of 
uncertainty if they mentioned some of the limitations or uncertainties of screening, 
such as the existence of false-positive or false-negative results, or other possible 
harms, such as anxiety for parents (although this was often expressed as 
exhortations not to worry).  Over a half of the leaflets (55/106) discussed the 
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limitations or uncertainties of screening. However, only 27/106 specifically 
referred to false results, whilst 41/106 referred to other possible harms 
Additional sources of support or information are provided in 23/106 of the leaflets. 
They referred to charitable or health service organisations providing support and 
further information. 
We judged information on the natural history of the conditions screened for and 
information about the importance of early detection through screening as an 
indication of the effectiveness of screening.  About two-thirds of the leaflets 
(70/106) contained this information, although the amount of information about the 
condition itself varied depending on whether it was a general leaflet outlining 
several conditions or was condition-specific.  For example, a general leaflet about 
screening includes the following information about congenital hypothyroidism: 
It is caused by an absent, small or improperly functioning thyroid gland.  
Lack of thyroid hormone slows brain development and growth.  Early 
treatment with daily thyroid hormone leads to normal mental and physical 
development [43]. 
In contrast, a leaflet [175] devoted entirely to congenital hypothyroidism describes 
in more detail, the condition, its causes, and how it is determined and treated. 
We found that 88/106 leaflets mentioned the benefits of screening generally; and 
24/106 mentioned the benefits to a particular population (often providing 
information about the incidence of each condition in the population).  Only a fifth 
21/106 of the leaflets, however, mentioned the benefits of screening generally and 
within a particular population.  A recent Scottish leaflet describes the benefits of 
screening as follows: 
Happily, most babies are perfectly healthy when they are born.  A small 
number however are born each year with problems.  This is why all babies 
are examined carefully after birth so that any problem identified in this way 
can be assessed and treated as soon as possible.  Some problems of body 
chemistry will not show up on the head to toe check but can be detected 
through a blood test…It is important that you realise that a delayed 
diagnosis of any of the conditions below may lead to permanent damage to 
your baby. [268] 
The leaflet then goes on to provide information on each of the conditions 
screened for.  For cystic fibrosis it says: 
Cystic fibrosis is a serious inherited condition that affects 1 in every 2,500 
babies born in Scotland.  The organs that are the most severely affected 
are the pancreas and the lungs, causing poor digestion and chest 
infections. 
Early treatment may help affected children to maintain good nutrition and 
minimise chest infections, leading to improved quality of life. The majority of 
affected babies will be picked up by the screening test [268]. 
Less than a quarter of the leaflets contained information about the limitations or 
possible harms of screening in terms of the risk of false negative (19/106) or false 
positive results (22/106).  Most of the leaflets therefore did not meet DISCERN’s 
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criteria for providing information about the risks. One UK information sheet 
includes the following information about false results: 
For most tests, some people with a positive result will turn out not to have 
the disorder (‘false positive’) and some with a negative result will 
subsequently be shown to have the disorder (‘false negative’).  Those 
people who have a positive result on the screening test are usually offered 
a further test (‘diagnostic test’), which will pick out much more accurately 
those who have the disorder [186]. 
The DISCERN tool asks whether the leaflet describes what would happen if no 
treatment were given.  To answer this question, we assessed leaflets according to 
whether they described the risks of not screening.  Analysis showed that 91 of the 
106 leaflets explained the importance of early detection and treatment for their 
child’s health.  However, only four leaflets specifically outlined the implications of 
not screening.  For example, one UK leaflet comments that “[screening] is very 
important since delayed diagnosis may cause your baby permanent brain 
damage” [194].  Similarly, a US leaflet warns parents that: 
A newborn baby can look healthy, but have a serious disease that cannot 
be seen.  If not treated, these diseases can lead to slow growth, blindness, 
brain damage, or possibly death.  Early treatment can help prevent these 
serious problems. [35] 
The DISCERN tool indicates that health information should ideally contain 
information about treatment choices.  We were therefore interested in whether 
newborn screening leaflets mentioned that screening was a choice or was 
mandatory.  We found that 41/106 leaflets contained this information (39%) and 
therefore met this criterion. 
Finally, the DISCERN tool asks whether the leaflet provides support for shared 
decision-making, such as questions to ask a health professional, or suggesting 
who to approach to discuss screening.  Our analysis showed that no leaflets we 
appraised addressed this issue. 
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5. RESULTS: APPLYING STANDARDS FOR POLICY 
DECISIONS 
Outline of Chapter 
This chapter considers the challenge of encapsulating criteria to inform population 
level decisions about screening to personal/ family level decisions about 
screening. It reflects on the process of interpreting and applying criteria for 
implementing screening programmes, and discusses how well screening 
information appears to reflect the principles underpinning the work of the National 
Screening Committee, with its explicit consideration of the viability, effectiveness 
and appropriateness of screening programmes.   
Key findings 
Interpreting policy making principles for personal/ family decisions 
• NSC criteria for policy making are specific and demanding, and have changed 
over the years. Translating them into criteria to judge information to be used for 
parents’ decisions was very challenging. 
Most leaflets included information about screening corresponding to the 
following principles of the NSC: 
• The screened condition should be an important health problem 
• The natural history of the condition should be adequately understood 
• There should be an agreed policy for follow-up of positive screening results 
• Adequate staffing and facilities for testing, diagnosis and treatment should be 
available 
Fewer than half the leaflets included information relating the following 
principles of the NSC: 
• All available prevention programmes should have been implemented as far as 
possible 
• Clinical management should be optimised prior to screening 
• The benefits of the screening programme outweighs the physical and possible 
psychological harm caused by screening 
• If carriers of a mutation are identified as a result of screening, the natural 
history of people with this status should be understood, including the 
psychological implications 
Approximately 1 in 10 or fewer included information relating the following 
principles of the NSC: 
• There exists a safe, precise and validated screening test 
• Effective early treatment is available, with evidence that early detection and 
treatment leads to better outcomes 
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• There is an agreed evidence-based policy about who should be offered 
treatment 
• Evidence exists from high-quality RCTs that the programme is effective in 
reducing mortality and morbidity; evidence also exists that the test accurately 
measures risk; or the information provided should be of value and readily 
understood 
• Opportunity costs should be balanced with other health care costs 
• All other options should have been considered to ensure no more cost-effective 
intervention could be introduced 
• There must be a plan for managing and monitoring screening and an agreed 
set of quality assurance standards 
• Evidence-based information for parents should be available explaining the 
consequences of testing, investigation and treatment. 
• If the test is for mutations the criteria used to select the subset of mutations to 
be covered by screening, if all possible mutations are not being tested, should 
be clearly set out 
5.1 Standards for policy decisions 
5.1.1 Applying NSC criteria 
We sought to determine the extent to which leaflets addressed the issues raised 
in the criteria set out by the UK National Screening Committee for appraising the 
viability, effectiveness and appropriateness of a screening programme.(6)  The 
details of this work are presented in appendix 6.  We included questions in our 
appraisal tool relating to the NSC’s criteria because of their specific focus on 
screening, despite their being related to policy decisions about implementing a 
particular health service rather than the provision of health information to 
consumers. 
A changing balance in policy between supporting public health priorities and 
encouraging realistic public expectations or informed choice for screening is 
evident since the National Screening Committee for England (NSC) published its 
first criteria for appraising the viability, effectiveness and appropriateness of a 
screening programme.(1) The NSC’s additional criteria in the second report are 
included to assist people further in making informed choices about screening.(2) 
Criteria added in a more recent report of the NSC’s Director relate specifically to 
the identification of unaffected carriers of the conditions and genetic testing.(6) 
Whilst the DISCERN criteria for information for patients on treatment choices 
required some adaptation when developing our own appraisal too, there was even 
greater leap when developing our tool to answer questions relating to the NSC’s 
stringent criteria for the implementation of screening programmes.  We did not 
include all NSC criteria in our leaflet appraisal tool because such criteria did not 
appear to be appropriate in the context of information leaflets or difficult to 
measure (e.g. evidence that the complete screening programme is clinically, 
socially and ethically acceptable to health professionals and the public; and 
anticipation of increased pressure for more screening), and were generous in our 
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evaluations of whether or not the information materials appraised conformed with 
the NSC criteria for implementing a screening programme.   
According to the NSC, ideally all the following criteria should be met before 
screening for a condition is initiated: 
5.1.2 The condition 
One of the National Screening Committee criteria is that the condition to be 
screened for should be an important health problem.  Analysis of our survey data 
showed that 91/106 leaflets (86%) provided information on the importance of 
screening newborns for particular conditions.  The Committee also maintains that 
the natural history of the condition should be adequately understood and that 
there should be a clear means of identifying the condition in an early 
asymptomatic phase.  Seventy of 106 leaflets (66%) contained information about 
the natural history of at least one of the four conditions, and the importance of 
screening. 
Another NSC criterion is that all available prevention programmes should have 
been implemented as far as possible.  To address this issue, we included 
questions in our appraisal tool about whether leaflets specified that apart from 
reproductive choice no prevention programmes exist for these conditions or 
provided other information about prevention programmes.  Most leaflets did not 
mention prevention programmes or reproductive choice as a means of prevention 
(64/106).  Of the 42 (40%) that did, 39/42 leaflets provided information on whether 
or not the conditions were inherited.  Seven leaflets mentioned preconception 
and/or antenatal screening and reproductive choice.  One leaflet specified that 
apart from reproductive choice no prevention programmes exist.  Three leaflets 
provided other information about prevention programmes. For example, one 
information sheet published by a US children’s hospital claims that: 
Four methods have worked to decrease the number of deaths due to birth 
defects by half since 1960:  taking 400 micrograms of the B-vitamin folic 
acid prior to and in the early weeks of pregnancy; new corrective surgical 
procedures; the specialized care and advanced technology of neonatal 
intensive care units; and new tests (screening) to detect and treat these 
defects at birth [33]. 
The NSC stipulates that if carriers of a mutation are identified as a result of 
screening the natural history of people with this status should be understood, 
including the psychological implications.  About half of the leaflets in this survey 
mentioned that babies might be identified as carriers (23/49) or that parents might 
be carriers (24/49). Nineteen leaflets mentioned the implications of carrier status 
for babies’ health.  Other leaflets mentioned the wider implications for families, 
including implications for family planning/reproductive choice (19/49), wider carrier 
testing for family members (10), how many carriers there are in the population (8), 
any uncertainty regarding diagnosis (8) and the psychological implications, such 
as anxiety (6). 
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5.1.3 The test 
We judged descriptions about how the blood was taken, the possibility of 
repeated tests, and information about false-positive and false-negative results as 
indicators of a safe, precise and validated screening test. Nine of the 106 leaflets 
(8%), all from the United States, contained this information.  With regard to NSC 
criteria that the distribution of test values in the target population should be known 
and a suitable cut-off level defined and agreed, our analysis showed that only five 
leaflets (5%) met these criteria, again from the USA, by providing information on 
the importance of screening a particular population for the conditions, the 
possibilities of false-negative and false-positive results and of a repeated test.  
Seventy-one (67%) of the leaflets described the circumstances in which follow-up 
would occur, indicated when the parents would hear about the necessity for 
further tests, stated when follow-up tests would occur, or indicated when parents 
would receive results of follow-up tests.  We determined that two-thirds of the 
leaflets therefore met the NSC criteria that there should be an agreed policy for 
follow-up for positive screening results (i.e. thought to be affected by the 
condition), and any further choices that might need to be made.   
The NSC stipulates that if the test is for mutations the criteria used to select the 
subset of mutations to be covered, if not all mutations are being tested, should be 
clearly set out.  We found that almost half of the leaflets mentioned carriers 
(49/106).  However less than half of these mentioned that babies could be 
identified as carriers (23/49), and only 12 of these mentioned that babies’ DNA 
might be tested.  Few leaflets mentioned the number of mutations tested (3) or 
that not all mutations were tested (4). 
5.1.4 The treatment 
The specification that there should be an effective early treatment for patients, 
with evidence that early detection and treatment leads to better outcomes was 
met by only 9/106 leaflets primarily because few cited evidence.  Similarly, only 
11/106 leaflets included information related to an agreed evidence-based policy 
about who should be offered treatment.   
Thirty-two leaflets (30%) provided information relating to NSC criteria that clinical 
management is optimised prior to implementing screening, in that they mentioned 
treatment for at least one of the four conditions and cited particular health 
professionals or specialists (e.g. paediatricians or metabolic specialists) who 
might become involved if treatment were indicated. 
5.1.5 The screening programme 
Thirteen leaflets (12%) met the criterion that there should be evidence from high 
quality randomised controlled trials (RCTs) that the screening programme is 
effective in reducing mortality and morbidity, that there should be evidence that 
the test accurately measures risk, or that information is provided about the test 
and its outcome must be of value and readily understood.  In this instance, we 
appraised leaflets according to whether they provided evidence and explained 
why the screening tests are important, or explained the importance of screening a 
particular population, provided evidence, and were easy to read/understand. 
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Less than half of the leaflets (47/106) provided information about the advantages 
and limitations of screening, including explaining why screening was 
recommended/important and information about false-negatives, false-positives 
and any other limitations.  
Another of the NSC’s criteria is that the opportunity cost of the screening 
programme should be economically balanced in relation to other medical costs.  
To address this issue we looked for information in leaflets pertaining to the cost-
effectiveness of a newborn screening programme, and found this information in 
five leaflets.  Four of these leaflets were from the USA; the one UK information 
sheet referred to the cost-effectiveness of screening in the context of raising funds 
for the purchase of purchasing new equipment for screening laboratories [207]. 
Our analysis showed that only four leaflets contained information that addressed 
the NSC’s criteria that there must be a plan for managing and monitoring 
screening and an agreed set of quality assurance standards. Three of the leaflets 
were from the USA, and one from Scotland. A comprehensive US overview for 
parents, states: 
The Program has numerous quality improvement, educational and 
monitoring mechanisms in place to assure that all infants are screened and 
that the results are valid.  However, biological variability, transfusions, and 
human error can result in missed cases [18]. 
In the case of meeting NSC criteria that adequate staffing and facilities for testing, 
diagnosis and treatment were concerned, we found that 97/106 (92%) of leaflets 
either mentioned follow-up to testing for diagnosis of a condition, or mentioned 
treatment for at least one of the four conditions. To determine whether the leaflets 
fulfilled NSC criteria that all other options should have been considered to ensure 
no more cost-effective intervention could be introduced, we included questions in 
our appraisal tool relating to information about prevention programmes or the 
difficulties of preventing of the conditions.  Analysis of the leaflets showed that 
42/106 (40%) of the leaflets specified either that no prevention programme was 
available, mentioned whether or not the conditions were inherited, preconception 
and/or antenatal screening and reproductive choice, or provided information about 
other means of prevention.  For example a UK information sheet for parents 
whose baby needs a repeat test for cystic fibrosis states that: 
Cystic fibrosis is an inherited disease….Approximately 1:25 of the 
population are carriers of the faulty gene which causes CF in their children 
[263]. 
Another UK leaflet on congenital hypothyroidism contains information on the 
causes of different types of hypothyroidism and whether or not they are inherited.  
Describing one form that is not inherited, and the cause unknown, the leaflet 
explains: 
Very early in your baby’s development in your uterus, their thyroid gland 
moves from the back of the tongue to its normal position in the neck.  In 
some babies this does not happen, which means that the gland cannot 
work properly… If you have one child with this type of congenital 
hypothyroidism, the chance of having another baby who is affected is very 
low [49]. 
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The NSC criteria stipulate that evidence-based information, explaining the 
consequences of testing and treatment should be made available to potential 
participants to help them make an informed choice.  To meet these criteria we 
determined that leaflets for parents should contain information on:  the importance 
of screening for the four conditions; the importance of screening this population; 
the possibilities of receiving false-negative or false-positive results or incurring 
other possible harms; identify the circumstances in which follow-up would occur; 
treatment for at least one of the four conditions; and provide sources of evidence.  
Only two information sheets met all these criteria (2%).  One was a public health 
education information sheet on newborn screening produced in the USA [137], 
the other was fact sheets produced for health professionals in the United States 
[204]. 
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6. DISCUSSION AND CONCLUSIONS 
Outline of Chapter 
This chapter summarises and discusses the findings of the survey in terms of its 
methodological strengths and weaknesses; how it compares with other surveys of 
evidence-based patient information; and how the leaflets found match information 
needs identified in a qualitative needs assessment.  It ends with our conclusions 
about the next steps required to prepare evidence-based parent information about 
newborn blood spot screening. 
Key messages 
Summary of findings 
• Most leaflets met at least basic criteria for providing information on the purpose 
of the leaflet, the aims of screening, conditions screened for, screening 
procedure, need for follow-up to confirm positive screening results, and 
treatment for the conditions. 
• Whilst most leaflets mentioned the benefits of screening, few addressed the 
issue of the possible harms, indicated that screening was a choice, discussed 
alternatives to screening, or gave information about when and how parents 
would receive results. 
• Few leaflets provided any sources of evidence for the information provided or 
how the information was developed. 
• The leaflets/information sheets did better on issues rooted in the principles of 
DISCERN for the provision of information on treatment choices, than on 
principles underpinning NSC decisions for the implementation of screening 
programmes. 
Strengths and weaknesses of the study 
• The 106 leaflets included in the survey were sourced through the internet and a 
selection of health service and support organisations in the UK; our searching 
strategy, however, was not exhaustive.   
• Two researchers performed double data extraction to ensure reliability of the 
appraisal tool, which, unlike the DISCERN instrument is not a validated tool. 
Relating to other surveys of patient information 
• Like other surveys of patient information, this study has found that information 
for parents is variable in quality and length and often biased in favour of 
screening. 
Matching the information needs identified in a qualitative needs assessment 
• Most leaflets met the criteria for providing ‘basic’ information and therefore met 
the needs of parents, most of whom perceived screening as routine for babies. 
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Recommendations 
•  We recommend the use of DISCERN with topic specific guidelines as a 
starting point for developing patient information. 
• We recommend appraising patient information with a topic specific tool to 
access good practice in information provision. 
6.1 Summary of findings 
Most leaflets provided information on the purpose of the leaflet, the aims of 
screening, conditions screened for, the screening procedure, the need for follow-
up to confirm positive screening results, and treatment for the conditions.  Even 
though the majority of leaflets might have met these criteria, however, the 
appraisers were generous when using the tool, and in some cases the information 
provided in the leaflets was scant and barely met the requirement.  In many 
cases, the majority of the leaflets did not meet the specific criteria.  For example, 
whilst most leaflets mentioned the benefits of screening, few addressed the issue 
of the possible harms, particularly false results, indicated that screening was a 
choice, discussed alternatives to screening, or gave information about when and 
how parents would receive results.  Fewer still provided any sources of evidence 
for the information provided or how the information was developed. 
The leaflets/information sheets did better on issues rooted in DISCERN criteria for 
the provision of information on treatment choices, than on NSC criteria for the 
implementation of a screening programme.  This is perhaps not surprising, 
considering that the former relates to patient information and the latter to 
screening policy criteria.  It also reflects previous policy and practice when 
newborn screening was performed as a routine test, and informed consent not 
sought from parents, who were told that ‘no news is good news’.   
6.2 Strengths and weaknesses of the study 
The study involved carrying out a wide search for information resources through 
the internet, and through a selection of health service and support organisations 
throughout the UK. Our searching strategy, however, was not exhaustive. Rather, 
we sought information that was accessible to UK maternity service users. To 
gather the full range of materials we purposely sought materials through UK 
maternity services and English language web sites of leading children’s hospitals. 
In developing our tool, we drew on both NSC criteria, which are topic specific and 
policy focussed, and DISCERN criteria, which are broader and more focussed on 
the patient/individual.  The researchers were generous in applying the criteria.  
Some leaflets were judged to have met the criteria even if the information 
provided was extremely brief.  
In developing and using the tool, two researchers performed double data 
extraction independently and compared results. This provided a quality check and 
highlighted issues for discussion.  
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Some contradictions were evident in categorising information as either presenting 
the benefits or difficulties/harms of screening.  For example, we have listed the 
possible need for repeat testing as a limitation of screening.  This is because 
repeat testing can cause worry for parents, and highlights some of the 
uncertainties of screening.  However, repeat testing could also be considered a 
benefit, in that it provides evidence of follow-up procedures to ensure that 
screening is done correctly and all affected babies detected.  
Nevertheless, the appraisal tool was able to distinguish parent information in 
terms of the type and style of information provided, and to indicate its reliability in 
terms of how and when it had been produced. 
6.3 Other surveys about patient information 
6.3.1 Surveys of screening and diagnosis information 
Other studies that have examined and evaluated patient information about 
screening have also concluded that the risks, limitations or difficulties were not 
openly discussed.  An Australian survey evaluating 58 leaflets on screening for 
breast cancer found that the benefits of screening were reported only ever as 
relative risk reduction and never as absolute risk reduction, thereby exaggerating 
the benefit.4   
Another study of 27 websites compared information on the possible benefits and 
harms of screening for breast cancer provided by different groups 5. The authors 
concluded that information provided by professional advocacy groups and 
government organisations were biased in favour of screening.  In contrast, 
information on consumer websites was more balanced and comprehensive. 
Other small qualitative studies have been carried out to evaluate existing patient 
information.  One such study of information on gastroscopy procedures in seven 
different hospitals, found that the quality of information varied between units, most 
leaflets lacked vital information, or included information that was confusing or 
ambiguous, and that information about risks was included in only one leaflet 6. An 
audit of informed consent procedures prior to surgical procedures found that the 
poorest area of information-giving was related to the potential complications of 
various procedures 7.  
6.3.2 Surveys employing DISCERN 
The Royal College of Anaesthetists (RCA) has also evaluated patient information 
materials with the specific aim of developing new information resources 8;9. Like 
us, they carried out an in-depth review of patient information with a view to 
developing new, better-quality patient information.  In the process of evaluating 
the leaflets, the RCA also developed an appraisal tool based on the DISCERN 
tool for evaluating patient information, as well as other tools for evaluating health 
information 8. 
Whilst our survey relied on adapting the original DISCERN instrument,3. and 
combining it with very focused topic specific criteria, since we completed our 
work, the DISCERN team has developed another instrument, DISCERN for 
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genetic testing, which would be applicable to some, but not all, of the conditions 
screened by the heel prick test.  
6.4 How do leaflets match parents’ information 
needs?  
A qualitative study we carried out simultaneously with this survey identified 
parents’ information needs. It highlighted the need for brief, non-technical 
information for parents, who largely perceived newborn blood spot screening as a 
routine procedure for all babies, and wanted only ‘basic’ information.11 Whilst 
many parents were not specific about what this might include, some said they 
would like to know the reasons for screening, the conditions they are screened 
for, when parents will receive the results, and what would happen if a baby tested 
positive for one of the conditions.  Most of the leaflets in this survey provided this 
type of ‘basic’ information.  For example, almost all of the leaflets (91/106) 
explained the aims of screening and three-quarters of them gave some 
description of the screened conditions (79/106).  The great majority of leaflets 
described the procedures for carry out the screening test.  Less than half, 
however indicated when parents would receive screening results, which reflects a 
finding of the qualitative study that most parents were told that the screening test 
was nothing to worry about, and that “no news was good news”. 
Most leaflets also mentioned the need for follow-up tests to check abnormal 
results (71/106), and most also mentioned treatment for at least one of the 
screened conditions (73/106).  Just over half of the leaflets were appraised as 
‘easy to read’ (56/106), which indicated that a significant number of leaflets did 
not meet parents’ requested criteria of ‘basic’ easily understood information.  
That two-thirds of the leaflets did not indicate whether or not screening was 
compulsory, and implied that screening was routine, supported the finding of our 
qualitative study that parents perceived screening as not subject to choice.  
Results from our qualitative study showed that many parents and health 
professionals supported screening as a routine procedure and expressed 
concerns that an ‘informed choice’ model would lead to a lower screening uptake. 
Whilst the model of informed choice promulgated by the National Screening 
Committee indicates the need to provide parents with more detailed information 
about the limitations as well as the benefits of screening, parents were generally 
not in favour of receiving detailed information about the limitations of screening.   
Many parents and health professionals regarded this as potentially reducing 
uptake of screening, which both, and particularly health professionals and parents 
of affected children regarded as undesirable.  Few parents told us they were 
interested in knowing the sources of information contained in a leaflet.  This is 
matched by our finding that the great majority of the leaflets provided no source of 
evidence for the information given (89/106).  Those that did (17/106) were 
generally intended for health professionals. 
It should be noted that the research evidence is in favour of screening either to 
improve health outcomes through early treatment, or to improve parents’ 
experiences of the diagnostic period 11-15, and that informed choice for screening 
is a relatively new phenomenon.  It is not surprising, therefore, that the leaflets 
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favour screening, and many do not support informed choice. With or without 
informed choice, in an increasingly legalistic climate there may be increased 
pressure to provide patients with detailed information to facilitate realistic 
expectations. The question also arises whether in the current climate of informed 
choice and with increasing patient information available some parents may begin 
to demand more information about screening 7.  
6.5 What has this survey achieved? 
This survey of currently available information on newborn blood spot screening 
forms part of the work we have undertaken to inform the development of parent 
and health professional information resources.  The other streams of work have 
included a systematic review of the literature on newborn screening and 
communication about it,3 an information needs assessment,11 and convening an 
expert advisory group to help develop information resources.   
This survey provided a list of topics, adapted from the appraisal tool, for members 
of the expert advisory group to debate. Structured discussion of these topics, 
around a table at its first meeting, and subsequently by email, led to a template for 
a pre-screening parent information leaflet. Inspection of the leaflets addressing 
topics within this template provided examples of wording, brief and extensive, for 
the expert advisory group to discuss at its second meeting. This discussion 
informed the first draft of a leaflet. A subsequent consultation of members and 
parents and health professionals interviewed in the parallel qualitative needs 
assessment refined this draft, making it ready for piloting with parents and their 
midwives between May and July 2004.   
Feedback on the resources was subsequently sought from parents and midwives 
(and other health professionals involved in taking the blood spots) through self-
administered questionnaires.  Feedback on these resources was also collected 
through the Programme Centre’s consultation during the summer of 2004.  Data 
received was analysed and the information resources modified in light of the 
feedback received. 
Final versions of the pre-screening leaflet and communication guidelines have 
been available for national distribution since October 2004.  The same methods 
have been applied to develop ‘results’ leaflets to be given to parents if their baby 
has a positive screening result (i.e. likely to be affected by one of the conditions).  
These provide more information about the implications of receiving a positive 
screening result, follow-up procedures and testing, and support services. 
6.6 Conclusions and recommendations 
We found combining the DISCERN criteria for patient information about treatment 
choices with NSC criteria for implementing screening programmes provided a 
practical route for structuring topics to be considered in parent information. We 
recommend the use of DISCERN with topic specific guidelines as a starting 
point for developing patient information. 
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We found appraising leaflets with a tool developed for the specific topic valuable 
for identifying the variation in parent information in terms of content and style. We 
recommend appraising patient information with a topic specific tool to 
access good practice in information provision.
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Appendix 1: The DISCERN Instrument 
SECTION 1. Is the publication reliable?  
1.  Are the aims clear?  
No  Partially  Yes 
1 2 3 4 5 
HINT Look for a clear indication at the beginning of the publication of: 
• what it is about  
• what it is meant to cover (and what topics are meant to be excluded)  
• who might find it useful  
If the answer to Question 1 is 'No', go directly to Question 3. 
2. Does it achieve its aims? 
No  Partially  Yes 
1 2 3 4 5 
HINT Consider whether the publication provides the information it aimed to as 
outlined in Question 1 
3. Is it relevant? 
No  Partially  Yes 
1 2 3 4 5 
HINT Consider whether:  
• the publication addresses the questions that readers might ask  
• recommendations and suggestions concerning treatment choices are realistic 
or appropriate.  
4. Is it clear what sources of information were used to compile the 
publication (other than the author or producer)? 
No  Partially  Yes 
1 2 3 4 5 
HINT: 
• Check whether the main claims or statements made about treatment choices 
are accompanied by a reference to the sources used as evidence, e.g. a 
research study or expert opinion.  
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• Look for a means of checking the sources used such as a 
bibliography/reference list or the addresses of the experts or organisations 
quoted, or external links to the online sources.  
Rating note: In order to score a full '5' the publication should fulfil both hints. Lists 
of additional sources of support and information (Question 7) are not necessarily 
sources of evidence for the current publication.  
5. Is it clear when the information used or reported in the publication was 
produced? 
No  Partially  Yes 
1 2 3 4 5 
HINT  Look for:  
• dates of the main sources of information used to compile the publication  
• date of any revisions of the publication (but not dates of reprinting in the case of 
print publications)  
• date of publication (copyright date).  
Rating note: The hints are placed in order of importance - in order to score a full 
‘5’ the dates relating to the first hint should be found.  
6. Is it balanced and unbiased? 
No  Partially  Yes 
1 2 3 4 5 
HINT Look for:  
• a clear indication of whether the publication is written from a personal or 
objective point of view  
• evidence that a range of sources of information was used to compile the 
publication, e.g. more than one research study or expert  
• evidence of an external assessment of the publication.  
Be wary if:  
• the publication focuses on the advantages or disadvantages of one particular 
treatment choice without reference to other possible choices  
• the publication relies primarily on evidence from single cases (which may not 
be typical of people with this condition or of responses to a particular treatment)  
• the information is presented in a sensational, emotive or alarmist way.  
7. Does it provide details of additional sources of support and information?  
No  Partially  Yes 
1 2 3 4 5 
HINT Look for suggestions for further reading or for details of other organisations 
providing advice and information about the condition and treatment choices.  
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8. Does it refer to areas of uncertainty?  
No  Partially  Yes 
1 2 3 4 5 
HINT: 
• Look for discussion of the gaps in knowledge or differences in expert opinion 
concerning treatment choices.  
• Be wary if the publication implies that a treatment choice affects everyone in 
the same way, e.g. 100% success rate with a particular treatment.  
SECTION 2. How good is the quality of information on treatment 
choices? 
N.B. The questions apply to the treatment (or treatments) described in the 
publication. Self-care is considered a form of treatment throughout this section.  
9. Does it describe how each treatment works? 
No  Partially  Yes 
1 2 3 4 5 
HINT  Look for a description of how a treatment acts on the body to achieve its 
effect.  
10. Does it describe the benefits of each treatment? 
No  Partially  Yes 
1 2 3 4 5 
HINT Benefits can include controlling or getting rid of symptoms, preventing 
recurrence of the condition and eliminating the condition, both short-term and 
long-term.  
11. Does it describe the risks of each treatment? 
No  Partially  Yes 
1 2 3 4 5 
HINT  Risks can include side-effects, complications and adverse reactions to 
treatment, both short-term and long-term. 
12. Does it describe what would happen if no treatment is used? 
No  Partially  Yes 
1 2 3 4 5 
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HINT: Look for a description of the risks and benefits of postponing treatment, of 
watchful waiting (i.e. monitoring how the condition progresses without treatment) 
or of permanently forgoing treatment.  
13. Does it describe how the treatment choices affect overall quality of life? 
No  Partially  Yes 
1 2 3 4 5 
HINT Look for:  
• description of the effects of the treatment choices on day-to-day activity  
• description of the effects of the treatment choices on relationships with family, 
friends and carers.  
14. Is it clear that there may be more than one possible treatment choice 
No  Partially  Yes 
1 2 3 4 5 
HINT  Look for:  
• a description of who is most likely to benefit from each treatment choice 
mentioned, and under what circumstances  
• suggestions of alternatives to consider or investigate further (including choices 
not fully described in the publication) before deciding whether to select or reject 
a particular treatment choice.  
15. Does it provide support for shared decision-making? 
No  Partially  Yes 
1 2 3 4 5 
HINT Look for suggestions of things to discuss with family, friends, doctors or 
other health professionals concerning treatment choices.  
SECTION 3. Overall Rating of the Publication 
16. Based on the answers to all of the above questions, rate the overall 
quality of the publication as a source of information about treatment 
choices 
Low  Moderate  High 
Serious or 
extensive 
shortcomings 
 Potentially 
important but 
not serious 
shortcomings
 Minimal 
shortcomings 
1 2 3 4 5 
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Appendix 2: NSC criteria for mounting a screening 
programme 
UK National Screening Committee 
Criteria for appraising the viability, effectiveness and appropriateness of a 
screening programme 
Ideally all the following criteria should be met before screening for a condition is 
initiated: 
The Condition 
1. The condition should be an important health problem 
2. The epidemiology and natural history of the condition, including development 
from latent to declared disease, should be adequately understood and there 
should be a detectable risk factor, disease marker, latent period or early 
symptomatic stage 
3. All the cost-effective primary prevention interventions should have been 
implemented as far as practicable 
4. If the carriers of a mutation are identified as a result of screening the natural 
history of people with this status should be understood, including the 
psychological implications. 
The Test 
5. There should be a simple, safe, precise and validated screening test 
6. The distribution of test values in the target population should be known and a 
suitable cut-off level defined and agreed 
7. The test should be acceptable to the population 
8. There should be an agreed policy on the further diagnostic investigation of 
individuals with a positive test result and on the choices available to those 
individuals 
9. If the test is for mutations the criteria used to select the subset of mutations to 
be covered by screening, if all possible mutations are not being tested, should 
be clearly set out. 
The Treatment 
10. There should be an effective treatment or intervention for patients identified 
through early detection, with evidence of early treatment leading to better 
outcomes than late treatment 
11. There should be agreed evidence based policies covering which individuals 
should be offered treatment and the appropriate treatment to be offered 
12. Clinical management of the condition and patient outcomes should be 
optimised in all health care providers to participation in a screening 
programme. 
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The screening programme 
13. There should be evidence from high quality Randomised Controlled Trials 
that the screening programme is effective in reducing mortality or morbidity. 
Where screening is aimed solely at providing information to allow the person 
being screened to make an “informed choice” (e.g. Down syndrome, cystic 
fibrosis carrier screening), there must be evidence from high quality trials that 
the test accurately measures risk.  The information that is provided about the 
test and its outcome must be of value and readily understood by the 
individual being screened.  
14. There should be evidence that the complete screening programme (test, 
diagnostic procedures, treatment/ intervention) is clinically, socially and 
ethically acceptable to health professionals and the public. 
15. The benefit from the screening programme should outweigh the physical and 
psychological harm (caused by the test, diagnostic procedures and 
treatment). 
16. The opportunity cost of the screening programme (including testing, diagnosis 
and treatment, administration, training and quality assurance) should be 
economically balanced in relation to expenditure on medical care as a whole 
(i.e. value for money) 
17. There should be a plan for managing and monitoring the screening 
programme and an agreed set of quality assurance standards 
18. Adequate staff and facilities for testing, diagnosis, treatment and programme 
management should be available prior to the commencement of the 
screening programme. 
19. All other options for managing the condition should have been considered 
(e.g. improving treatment, providing other services), to ensure that no more 
cost effective intervention could be introduced or current interventions 
increased within the resources available. 
20. Evidence-based information, explaining the consequences of testing, 
investigation and treatment, should be made available to potential 
participants to assist them in making an informed choice. 
21. Public pressure for widening the eligibility criteria for reducing the screening 
interval, and for increasing the sensitivity of the testing process, should be 
anticipated.  Decisions about these parameters should be scientifically 
justifiable to the public. 
22. If screening is for a mutation the programme should be acceptable to people 
identified as carriers and to other family members.
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Appendix 3: Bringing together DISCERN and NSC criteria to develop our 
appraisal tool  
This table illustrates how we brought together the DISCERN and NSC criteria, grouped in the following themes:  
• The conditions 
• Different options 
• Decision-making 
• The intervention process 
• What happens next 
• The effectiveness of the intervention 
This enabled us to identify a list of criteria on which we could judge parent information about newborn blood spot screening.  
Types of information NSC criteria for implementing screening 
programmes 
DISCERN criteria for patient information 
about treatment outcomes 
Criteria on which existing leaflets might be judged 
A. The conditions • the importance of the health problems 
• the natural history of the conditions 
• the natural history of people with carrier 
status (if the genetic carriers of a condition 
are identified as a result of screening) 
• who it's relevant to and in what context 1. clarity about who this information is for and in what 
context 
2. the importance of the 4 conditions screened for and 
a summary of their natural history (including CF and 
sickle carrier babies) 
3. The aims of screening 
B. Different options 
 
• any primary prevention interventions which 
have been implemented 
• information which is balanced and unbiased
• presenting evidence from a range of 
sources 
4. an outline of any prevention programmes for these 
4 conditions (or why there are no other prevention 
programmes) 
5. a clear and unbiased description of what the 
alternatives to screening are for parents and their 
babies 
6. ensure that evidence is cited from a range of 
different sources in order to provide balanced 
information 
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Types of information NSC criteria for implementing screening 
programmes 
DISCERN criteria for patient information 
about treatment outcomes 
Criteria on which existing leaflets might be judged 
C. Decision-making • NSC's definition of screening specifies that 
the target population is  "offered a test", and 
that "the individual to whom it is offered is 
helped to make an informed choice" (ref - 
second report).  
• the distribution of test values in the target 
population, and the defined and agreed cut-
off level 
 
• the fact that parents have a choice (and 
support for shared decision making) 
• the aims of the information leaflet 
• the relevance of the content to the intended 
audience 
• the date of publication 
• the fact that (and why?) this is evidence-
based information 
• information which is balanced and unbiased
• the sources of the information contained in it 
(dated) 
• additional sources of support and 
information 
• suggestions of alternatives to consider 
before deciding whether or not to have your 
baby screened 
• what would happen if your baby was not 
screened 
7. a clear description of the choice parents are being 
offered 
8. a clear description of the accuracy of the test results 
(the distribution of test values and the agreed cut off 
levels) 
9. a clear description of the alternatives to screening 
10. a clear description of what would happen if your 
baby wasn't screened 
11. the aims of the leaflet: in providing information to 
inform parents' choice 
12. how the information provided is based on evidence 
13. when the information provided was developed 
14. the sources (and dates) of the information included 
15. additional sources of support and information to 
assist with the decision-making process 
D. The intervention 
process 
• the value for money, balancing the costs of 
screening and expenditure on health care in 
general 
• the provision of adequate staffing and 
facilities of testing, diagnosis, treatment and 
programme management 
 16. the costs of screening and subsequent diagnosis 
and treatment to parents  
17. the cost-effectiveness of screening 
18. an outline of the services provided within the 
screening programme  
E. What happens next • the provision of adequate staffing and 
facilities of testing, diagnosis, treatment and 
programme management  
• the agreed policy on the further diagnostic 
investigation of babies with a positive test 
result and the choices which those parents 
will have. 
• the agreed policies covering which 
individuals are offered treatment and the 
appropriate treatment to be offered. 
• additional sources of support and 
information 
19. a continuation of the outline in (4), including the 
services available for testing, diagnosis and 
treatment 
20. the processes followed for different screening 
outcomes, and any subsequent choices parents will 
have. 
21. specifically, the process of following up affected 
babies, and how these cases are managed on a 
clinical level  
22. additional sources of support and information (and 
about different outcomes??) 
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Types of information NSC criteria for implementing screening 
programmes 
DISCERN criteria for patient information 
about treatment outcomes 
Criteria on which existing leaflets might be judged 
• the situation re clinical management of 
those with the condition  
• the evidence that there is an effective 
treatment for babies identified through early 
detection, with evidence of early treatment 
leading to better outcomes than late 
treatment    
• that (and how) screening works  
• the evidence from high quality randomised 
controlled trials that the screening 
programme is effective in reducing mortality 
and morbidity 
• if the test is for mutations the criteria used to 
select the subset of mutations to be covered 
by screening if all possible mutations are not 
being tested 
• where screening is aimed solely at providing 
information to allow the person being 
screened to make an ‘informed choice’ (eg 
Downs screening) there must be evidence 
from high quality trials that the test 
accurately measures risk; and that  the 
information is of value and readily 
understood by the individual being screened
• any areas of uncertainty (either within the 
evidence or due to lack of evidence) 
• the evidence that the complete screening 
programme (including screening test, 
diagnostic procedures, 
treatment/intervention) is clinically, socially 
and ethically acceptable to health 
professionals and the public 
• if screening is for a mutation the programme 
should be acceptable to people identified as 
carriers and to other family members 
• the benefits of screening 
• description of who is most likely to benefit 
from screening (or not screening) 
• the safety and validation of the screening 
tests 
• the risks of screening 
F. Effectiveness of 
intervention 
• evidence that the test is acceptable to the 
population 
• the risks of not screening 
23. the effectiveness of screening on affected babies 
24. the effectiveness of screening on affected babies 
compared to later diagnosis based on symptoms 
25. the effects of screening on the screened population 
in general: 
• the benefits of screening 
• the risks of screening 
• the benefits of not screening 
• the risks of not screening 
26. the evidence that the complete screening 
programme (information, screening test, diagnostic 
procedures, treatment) is clinically, socially and 
ethically acceptable to health professionals and the 
public 
 
NB might include the effectiveness of: 
• receiving information about the screening test 
• being offered a choice (or not) about screening 
• having the test performed on your baby 
• receiving a true positive result 
• receiving a true negative result 
• receiving a false positive result 
• following a false negative result 
• receiving a carrier result 
 
on the following range of outcomes:  
• the physical health of the baby (in particular as 
measured by number of hospital admissions AND/OR 
the incidence of infections) 
• growth (height and weight) of the child  
• the physical health of the parent(s) 
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Types of information NSC criteria for implementing screening 
programmes 
DISCERN criteria for patient information 
about treatment outcomes 
Criteria on which existing leaflets might be judged 
• evidence that the benefits of the screening 
programme outweigh the physical and 
psychological harm (caused by the test, 
diagnostic procedures and treatment) 
• how screening affects overall quality of life 
• the effects of screening on day to day 
activity 
• the effects of screening on relationships with 
family friends and carers 
• family relationships 
• the relationship between the family and the health 
service 
• the psychological health of the parent(s), including 
anxiety (as well as other emotional responses) 
• measures of quality of life (? various) 
• the response of the community or wider family, 
including stigma  
• future reproductive choices by the parents 
• future choices about screening for a) other family 
members AND b) subsequent newborns 
• parents' understanding and knowledge, including 
retention of knowledge 
• parents' satisfaction with the screening service 
• parents' communication and decision-making skills 
• financial costs to the health service 
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Appendix 4: Appraisal tool for leaflets 
Newborn bloodspot screening data extraction  
April 2003 
Section A: Purpose of Leaflet 
A.1 Is it clear whom the leaflet is for? A.1.1 Yes, Parent/Carer 
A.1.2 Yes, Family 
A.1.3 Yes, Adult 
A.1.4 Yes, Child 
A.1.5 Yes, Health Professional 
A.1.6 No 
A.2 If the leaflet states whom it's for, how is 
this indicated? 
A.2.1 In the title of the leaflet 
A.2.2 In the text 
e.g. says 'your baby' or 'my baby' 
A.3 Is it clear from the leaflet when in the 
screening pathway this information would be 
given? 
A.3.1 Yes, Before screening takes place 
(antenatally or postnatally) 
A.3.2 Yes, As part of the consent process 
A.3.3 Yes, At time of the test 
A.3.4 Yes, With screening results 
A.3.5 Yes, After confirmed positive diagnosis 
A.3.6 Yes, Other timing in which information is 
given (please specify) 
A.3.7 No 
Section B: Background to screening programme 
B.1 Does the leaflet give the aims of/reasons 
for screening 
Includes statistical information on number of 
cases of particular condition in a specific 
population (ethnic or geographic) 
B.1.1 Yes, Explains why the tests are 
recommended/important (list conditions 
covered) 
B.1.2 Yes, Explains importance to screen a 
particular population (list conditions covered) 
B.1.3 No 
B.2 Does the leaflet describe the natural 
history of the conditions? 
B.2.1 Yes, for PKU 
B.2.2 Yes, for CHT 
B.2.3 Yes, for SC disorders 
B.2.4 Yes, for CF 
B.2.5 Yes, for other disorders 
B.2.6 No 
B.3 Does the leaflet discuss available 
prevention programmes and/or the difficulties 
of prevention? 
B.3.1 Yes, Specifies that apart from 
reproductive choice, no prevention 
programmes exist 
B.3.2 Yes, Indicates whether or not disorders 
are inherited 
B.3.3 Yes, Mentions preconception and/or 
antenatal screening and reproductive choice 
B.3.4 Yes, Provides other information about 
prevention programmes 
B.3.5 No 
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Section C: Process of screening 
C.1 Does the leaflet describe the procedures 
for doing the heel-prick test? 
C.1.1 Yes, Describes how the blood sample is 
taken 
C.1.2 Yes, Indicates that it may be 
uncomfortable for the baby 
C.1.3 Yes, Describes how pain may be eased 
for baby 
C.1.4 Yes, Describes how bloodspots placed 
on the Guthrie card 
C.1.5 Yes, Describes what happens next to 
the card/blood sample 
C.1.6 Yes, Describes how results are reported
C.1.7 Yes, Discusses the possibility of a 
repeated test 
C.1.8 Yes, Indicates storage/possible later 
use of cards 
C.1.9 Yes, Other (please specify) 
C.1.10 No 
C.2 Does the leaflet indicate when the parents 
will receive or be asked to collect the 
screening results? 
C.2.1 Yes, Positive (specify time) 
C.2.2 Yes, Negative (specify time) 
C.2.3 No 
C.3 Does the leaflet indicate that screening is 
not compulsory/mandatory? 
C.3.1 Yes, Outlines choices/alternatives to 
screening 
C.3.2 Yes, Recommends screening 
C.3.3 Yes, Discusses possible implications of 
not screening 
C.3.4 Yes, Outlines processes for 
accepting/refusing 
C.3.5 No, Indicates that it is 
compulsory/mandatory (e.g. in USA) 
C.3.6 No, Specifies circumstances where 
refusal is acceptable 
C.3.7 No, Nothing specified 
C.4 Does the leaflet discuss the limitations of 
screening and the possible harms, e.g. false 
negatives, false positives? 
Refers to screening results only, not 
diagnostic test results. 
C.4.1 Yes, False negative 
C.4.2 Yes, False positive 
C.4.3 Other (please specify) e.g. "Don't worry"
C.4.4 No 
C.5 Does the leaflet mention the costs of 
screening? 
C.5.1 Yes, Costs to parents 
C.5.2 Yes, Costs to the health service 
C.5.3 Yes, Costs to health insurers (e.g. in 
USA) 
C.5.4 No 
C.6 Does the leaflet discuss the cost-
effectiveness of screening? 
C.6.1 Yes 
C.6.2 No 
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Section D: Follow-up to screening 
D.1 Does the leaflet mention the need for 
further testing to confirm diagnosis? 
D.1.1 Yes, Identifies circumstances in which 
follow-up would occur 
D.1.2 Yes, Indicates when parents will hear 
about necessity for follow-up tests 
D.1.3 Yes, States when tests might occur 
D.1.4 Yes, Indicates when parents will receive 
results of follow-up tests 
D.1.5 No 
D.2 Does the leaflet mention treatment for any 
of the four conditions? 
D.2.1 Yes, PKU 
D.2.2 Yes, CHT 
D.2.3 Yes, SC 
D.2.4 Yes, CF 
D.2.5 No 
D.3 Does the leaflet mention any related 
services? 
D.3.1 Yes, support organisations (within 
health service or charity) 
D.3.2 Yes, Support re decision-making 
D.3.3 Yes, Counselling 
D.3.4 Yes, Health professional/specialist 
D.3.5 Yes, Other (e.g. quality assurance, 
supplementary screening) 
D.3.6 No 
Section E: Production of the leaflet 
E.1 Are sources of evidence indicated on the 
leaflet? 
For example, included named specialist or 
specialist organisation. 
E.1.1 Yes, evidence provided 
E.1.2 Yes, dates of evidence provided 
E.1.3 Yes, more than one type of source used
(specify type, e.g. policy document, research 
paper, specialist reviewer) 
E.1.4 No 
E.2 Is specific information provided linked to 
evidence? 
E.2.1 Yes (please specify) 
E.2.2 No 
E.3 Does the leaflet indicate when the leaflet 
was developed? 
E.3.1 Yes (give details) 
E.3.2 No 
E.4 What is the level of complexity of the 
leaflet? 
E.4.1 Easy to read (technical terms explained 
or stated in lay language) 
E.4.2 Some technical terms not explained or 
confusing 
E.4.3 Requires some expert/medical 
knowledge to understand 
E.5 Does the leaflet indicate how the 
information was developed? 
E.5.1 Yes 
E.5.2 No 
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Appendix 5: Leaflets and Information Sheets 
included in the Survey 
1. Gilham, P. (2002) Notification letter. Reading, UK, Sickle Cell and Thalassaemia 
Service, Haematology Department, Reading  
5. Gilham, P. (2002) Notification letter. Reading, UK, Sickle Cell and Thalassaemia 
Service, Haematology Department  
12. Brayden, R. (1999) Newborn Screening Tests. Orange County, US, Children's Hospital 
of Orange County - http://www.choc.com/   
13. (2003) Newborn Screening Program Overview. California, US, California Department of 
Health Services  
14. (2001) Important Information for Parents about the Newborn Screening Test. California, 
US, California Department of Health Services - http://www.dhs.cahwnet.gov/   
18. (2003) Newborn Screening Program Overview for Parents. California, US, California 
Department of Health Services - http://www.dhs.ca.gov/   
33. (2002) The importance of newborn screening. US, Akron Children's Hospital - 
http://www.akronchildrens.org/  
34. (2002) Newborn Screening: For Your Baby's Health. New York, US, NYS Department 
of Health - http://www.wadsworth.org/  
35. (2003) Parents' Page: Newborn Screening in Wisconsin. Wisconsin, US, Wisconsin 
Division of Public Health Newborn Screening - http://slh.wisc.edu/  
36. (2003) Most Important Health Messages for Patients. March of Dimes - 
http://www.marchofdimes.com/  
38. (2003) Newborn Screening Tests. US, March of Dimes - http://209.10.141.228/  
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US, March of Dimes - http://209.10.141.228/  
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Victoria - http://www.genetichealthvic.net.au/  
43. (2001) Tests to Protect Your baby. Why early diagnosis is important to your baby's 
future. New South Wales, Australia, NSW Newborn Screening Programme - 
http://www.health.nsw.gov.au/  
45. (2000) Information for parents/carers. Further investigations requested for congenital 
hypothyroidism. New South Wales, Australia, New South Wales Newborn Screening 
Programme - http://www.chw.edu.au/  
46. (2000) Information for parents / carers for cystic fibrosis. New South Wales, Australia, 
New South Wales Newborn Screening Programme - http://www.chw.edu.au/  
49. (2002) Congenital Hypothyroidism. London, UK, Institute of Child Health and Great 
Ormond Street Hospital for Children - http://www.ich.ucl.ac.uk/  
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56. (2003) Overview of Newborn Screening for Defects. Stanford, US, Lucile Packard 
Children's Hospital, http://www.lpch.org/   
71. (2001) Child Health A-Z: Sickle Cell Disease. Boston, USA, Children's Hospital Boston 
- http://www.web1.tch.harvard.edu/   
89. (2003) Newborn Screening Tests. Pittsburg, US, Children's Hospital of Pittsburg - 
http://www.chp.edu/   
104. (2000) The Blood Test on Newborn Babies. Leeds, UK, The Leeds Teaching Hospitals  
106. Neonatal Biochemical Screening - The Guthrie Test. Addenbrooke's NHS Trust  
107. (2000) Your baby's blood test. Northampton, UK, Northamptonshire Neonatal 
Screening Service  
108. Neonatal Screening - A practical guide. Belfast, UK, The Royal Hospitals  
128. Hulse, T. (1998) Hypothyroidism. London, UK, British Society for Paediatric 
Endocrinology and Diabetes - http://www.bsped.org.uk/  
135. (2003) Kentucky's Newborn Screening Program. Kentucky, US, KY Cabinet for Health 
Services - http://publichealth.state.ky.us/  
136. (1997) Ask NOAH About Pregnancy. PKU Public Health Educational Information 
Sheet, Genetic Series. March of Dimes Birth Defects Foundation - http://www.noah-
health.org/  
137. (1999) Newborn Screening Tests - Public Health Education Information Sheet. White 
Plains, US, March of Dimes - http://www.noah-health.org/  
141. Beasley, J. (1997) Sickle Cell Newborn Screening - Frequently Asked Questions 
(FAQs). Georgia, US, The Georgia Sickle Cell Centre - http://www.emory.edu/  
153. (2003) What Parents should Know - A Summary. New England, US, New England 
Newborn Screening Program - http://www.umassmed.edu/  
157. (2003) Answers to Common Questions about Newborn Screening. USA, New England 
Newborn Screening Program  
159. (2003) Newborn Screening Case Management Program. Texas, US, Texas 
Department of Health - Newborn Screening - http://www.tdh.state.tx.us/  
160. (1998) Newborn Screening Case Management Program: Hypothyroidism and Your 
Infant. Texas, US, Texas Department of Health - http://www.tdh.state.tx.us/  
161. (2003) Newborn Screening Case Management Program. Congenital Hypothyroidism. 
Texas, US, Texas Department of Health - http://www.tdh.state.tx.us/  
167. (1999) Phenylketonuria (PKU). Texas, US, Texas Department of Health - 
http://www.tdh.state.tx.us/  
174. (2003) Nebraska Newborn Screening Program - Practitioner's Manual. Nebraska, US, 
Nebraska Department of Health and Human Services - http://www.hhs.state.ne.us/  
175. (2003) Congenital Hypothyroidism. New York, USA, Wadsworth Centre. New York 
State Department of Health - http://www.wadsworth.org/  
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177. Newborn Screening for Cystic Fibrosis. Pittsburg, US, University of Pittsburg, USA - 
http://www.pitt.edu/  
183. A Simple Test Could Save Your Baby's Life - A Parent's Guide to Newborn Screening. 
Save Babies Through Screening - http://www.savebabies.org/  
186. (2002) Antenatal, Neonatal and Childhood Screening:  A summary for professionals. 
Contact a Family - http://www.cafamily.org.uk/  
194. (2001) The Neonatal Screening Test - Guidance for Parents. Sheffield, UK, Trent 
Region Neonatal Metabolic Screening Service  
195. The Heel-Prick Test. Blood Screening Tests for Newborn Babies. Surrey, UK, South 
West Thames Regional Infant Screening Service  
200. (2002) Genetics, Carrier Testing, Tests during Pregnancy and for Newborn Babies. 
London, UK, Cystic Fibrosis Trust - http://www.cftrust.org.uk/   
202. (1998) Overview: Newborn Screening. US, National Newborn Screening and Resource 
Center - http://genes-r-us.uthscsa.edu/  
204. (1996) Newborn Screening Fact Sheets. US, American Academy of Pediatrics - 
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Appendix 6: Applying principles underpinning 
DISCERN criteria to information about screening 
DISCERN is designed to appraise information about treatment choices. In applying 
DISCERN questions to screening information, we needed to replace treatment choices with 
choices about whether to not to screen. If leaflets were to provide parents with the same 
information that is required by the DISCERN they would include the following information: 
 DISCERN criteria Acceptable answer to 
our question 
Question/answer from 
our appraisal tool 
1. Are the aims of the 
information clear? 
It’s clear about who the 
leaflet is for 
AND  
It’s clear when the leaflet 
would be given 
A.1.1 – A.1.5 
AND 
A.3.1 – A.3.6 
2.  Does it achieve its aims?  Our appraisal tool does not 
address this question 
3. Is it relevant? Explains importance to 
the population 
B.1.2 or B.1.2 
4. Is it clear what sources of 
information were used to 
compile the publication 
(other than the author or 
producer)? 
That evidence is provided 
and isn’t just the author 
E.1.3  
OR E.1.1 (as long as this is 
not just the name of the 
author – check ‘details’ 
box) 
5. Is it clear when the 
information used or 
reported in the publication 
was produced? 
Dates of evidence 
provided  
AND not just author and 
date of last update 
E.1.2  
AND 
E.1.1 (as long as this is not 
just the name of the author 
– check ‘details’ box) 
6. Is it balanced and 
unbiased? 
Mentioned false-positive  
AND  
Mentioned false-negative 
OR 
Other possible harms 
(e.g. worry) 
C.4.1 
AND 
C.4.2 
OR 
C.4.3 
7. Does it provide details of 
additional sources of 
support and information? 
Mentioned support 
organizations 
D.3.1 
8. Does it refer to areas of 
uncertainty? 
Mentioned false-positive  
AND  
Mentioned false-negative  
OR 
Other possible harms 
(e.g. worry) 
C.4.1 
AND 
C.4.2 
OR 
C.4.3 
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 DISCERN criteria Acceptable answer to 
our question 
Question/answer from 
our appraisal tool 
9. Does it describe how 
each treatment works? 
Does it mention the 
natural history of the 
conditions 
AND  
The importance of 
screening 
B.2.1 OR B.2.2 OR B.2.3. 
OR B.2.4 
AND 
B.1.1 
10. Does it describe the 
benefits of each 
treatment? 
Does it mention the 
benefits of screening  
 
 
B.1.1 OR B.1.2 
 
11. Does it describe the risks 
of each treatment? 
Does it describe the risks 
of screening (false 
positives and/or false 
negatives or anxiety) 
AND  
The risks of not screening 
(natural history and why 
tests are important) 
C.4.1 OR C.4.2 OR C.4.3 
 
AND 
 
B.2.1 AND B.2.2 OR B.2.3. 
OR B.2.4 
AND 
B.1.1 
12. Does it describe what 
would happen if no 
treatment were used? 
The risks of not screening 
(natural history and why 
tests are important) 
B.2.1 AND B.2.2 OR B.2.3. 
OR B.2.4 
AND 
B.1.1 
13. Does it describe how the 
treatment choices affect 
overall quality of life? 
 Our appraisal tool does not 
address this question 
14. Is it clear that there may 
be more than one 
possible treatment choice 
Mentions choices 
OR  
States that it’s mandatory 
C.3.1 
OR 
C.3.5 
15. Does it provide support 
for decision-making 
Mentions support re 
decision-making 
D.3.2 
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Appendix 7: Applying principles underpinning NSC 
criteria to information available to parents 
If leaflets were to provide parents with the same information that is required by the NSC, as 
specified in the first report of the NSC (1998) (in order to decide that a screening programme 
should be introduced) they would include the following information: 
 NSC criteria Acceptable answer to 
our question 
Question/answer from 
our appraisal tool 
1.1 That the condition is an 
important health problem 
Explains importance of 
tests 
B.1.1 OR B.1.2 
1.2 The natural history of the 
condition 
That there is a clear 
means of identifying the 
condition during an early 
asymptomatic phase 
Natural history of at least 
one of the conditions 
AND  
Explains importance of 
tests 
B.2.1 OR B.2.2 OR B.2.3 
OR B.2.4 
AND 
B.1.1 OR B.1.2 
1.3 All available prevention 
programmes have been 
implemented as far as 
possible 
Specifies that there are no 
prevention programmes 
OR provides other info 
about available prevention 
programmes 
B.3.1 
OR 
B.3.4 
1.4  That there is a safe, 
precise and validated 
screening test 
Description of how the 
blood is taken 
AND  
Description of the 
possibility of repeated 
tests 
AND  
False positive rates 
AND 
False negative rates 
C1.1 
AND 
C1.7 
AND  
C.2.1 
AND 
C.2.2 
1.5 Distribution of test values 
and clear cut off levels 
Our appraisal tool does 
not address this question 
 
1.6 Test is acceptable to 
population 
Our appraisal tool does 
not address this question 
 
1.7  Agreed policy for follow up 
for positive screens, and 
any further choices which 
might need to be made 
Circumstances in which 
follow-up would occur 
OR  
Indication when parents 
will hear about the 
necessity of further tests 
OR 
Statement about when 
follow-up tests might occur
OR  
Indication of when parents 
will receive results of 
follow up tests. 
D.1.1 
OR 
D.1.2 
OR 
D.1.3 
OR  
D.1.4 
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 NSC criteria Acceptable answer to 
our question 
Question/answer from 
our appraisal tool 
1.8 Effective early treatment, 
with evidence that early 
detection and treatment 
leads to better outcomes 
Mentions treatment for at 
least one of the conditions
AND 
Explains why the tests are 
important 
AND  
Provides evidence 
B.1.1  
AND  
B.2.1 OR B.2.2 OR B.2.3 
OR  B.2.4  
AND 
E.1.1 
1.9 Agreed evidence-based 
policy about who should 
be offered treatment 
Mentions treatment 
AND 
Provides the evidence 
D.1.1 
AND 
E.1.1 
1.10 Clinical management 
optimized prior to 
screening 
Mentions treatment of at 
least one of the four 
conditions 
AND 
Mentions a health 
professional / specialist 
D.2.1 OR D.2.2 OR D.2.3 
OR D.2.4 
AND 
D.3.4 
1.11 Evidence from high quality 
RCTs that the programme 
is effective in reducing 
mortality and morbidity 
Provides evidence 
AND 
Explains why tests are 
important 
 
 
E.1.1 
AND 
B.1.1 
 
 
1.12 Evidence that the 
complete screening 
programme is clinically, 
socially and ethically 
acceptable to health 
professionals and the 
public 
Our appraisal tool does 
not address this question 
 
1.13 That the benefits of the 
screening programme 
outweighs the physical 
and psychological harm 
Provides full details about 
the advantages and 
limitations of the screening 
programme, including: 
 
Explains why the tests are 
recommended/important 
AND 
Discusses false-negatives 
OR false positives OR 
other limitations 
 
B.1.1 
AND 
C.4.1 OR C.4.2 OR C.4.3 
1.14 Opportunity costs should 
be balanced with other 
health care costs – value 
for money 
Any mention of cost-
effectiveness 
C.6.1 
1.15 Must be a plan for 
managing and monitoring 
screening and an agreed 
set of quality assurance 
standards 
Refers to quality 
assurance mechanisms 
D.3.5 – search for quality 
assurance 
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 NSC criteria Acceptable answer to 
our question 
Question/answer from 
our appraisal tool 
1.16 Adequate staffing and 
facilities for testing, 
diagnosis and treatment 
Mention of follow up 
testing 
OR  
Mention of treatment 
D.1.1 OR D.1.2 OR D.1.3 
OR D.1.4 
OR 
D.2.1 Or D.2.2 OR D.2.3 
OR D.2.4 
1.17 All other options for 
managing the condition 
should have been 
considered  
Specifies no prevention 
programme available 
OR  
Indicates whether or not 
disorders are inherited 
OR  
Mentions preconception 
and/or antenatal screening 
and reproductive choice 
OR  
Provides other information 
about prevention 
programmes 
B.3.1 
OR 
B.3.2 
OR 
B.3.3 
OR 
B.3.4 
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affected When someone has a condition, it is said that they are affected. A child, 
who is affected with CHT, is a child who has CHT. 
 
antenatal screening Antenatal screening, is screening which is carried out before a baby is 
born. This can include doing tests on the pregnant mother, her partner 
or the unborn baby. Antenatal screening includes tests for a wide 
range of conditions, including haemoglobinopathies.. 
 
audit This is the evaluation of clinical performance against standards or 
through comparing the same services in different settings, with the aim 
of improving health service delivery. 
 
blood sampling Blood sampling is the collecting of a small amount of blood referred to 
as a blood sample. In the case of newborn screening it refers to the 
collection of a small amount of blood from the baby's heel at about one 
week of age. This is done by pricking the heel with a lancet or similar 
device, to draw drops of blood which are then dropped onto a Guthrie 
card.   
 
blood spot When newborn babies are about a week old a blood sample is taken 
from their heel. This is sometimes referred to as the heel prick test. 
Blood from the baby’s heel is dropped onto a special type of filter paper 
called a Guthrie card and stored as a series of bloodspots. A number 
of tests are then carried out on these bloodspots for the purposes of 
newborn screening. These tests are often called newborn bloodspot 
screening to distinguish them from other types of newborn screening, 
such as hearing screening, which don’t involve this blood test. These 
bloodspots can be stored for very long periods of time. 
 
carrier Everyone inherits two copies of a gene – one from their father and one 
from their mother.  One or both copies of a gene may have a change 
(mutation) that alters the function of the gene.  For some gene pairs, 
disease only results if both members of that gene pair have a mutation. 
A carrier is someone who has one copy of a changed (mutated) gene in 
a gene pair, where disease occurs only if both members have a 
mutation, and therefore has no symptoms and no disease.  The carrier 
can pass on the changed gene to their offspring.  If a person inherits 
mutations in the same gene from both parents then they will have the 
disorder associated with mutations in two copies of that particular gene 
pair e.g. cystic fibrosis, sickle cell anaemia or 
phenylketonuria.  Carriers are also referred to as heterozygotes.  
 
Child Health Department 
(often referred to as 
'child health') 
The Child Health Department keeps records about each child who is 
born within their area of responsibility. When a mother gives birth the 
Child Health Department is notified of the birth. The results of newborn 
screening tests are also reported to the Child Health Department. 
 
Appendix 8: Glossary 
Survey of information resources on newborn blood spot screening for parents and health 
professionals 65 
Child Health Subgroup The Child Health Subgroup is a smaller group within the National 
Screening Committee, which concentrates on the screening of children. 
 
condition Many different words are used to describe illnesses. They are 
sometimes called diseases, or disorders, or conditions. 
 
congenital 
hypothyroidism (CHT) 
Congenital hypothyroidism - a condition which newborn babies are 
tested for. Hypothyroidism is a condition in which not enough thyroid 
hormone is produced. Thyroid hormone, or thyroxine (T4), is made by 
the thyroid gland, which is located in the front of the neck just beneath 
the Adam's apple. In most cases of hypothyroidism, the problem arises 
from an absent or under-functioning thyroid gland. In rare instances 
there can be a normally functioning gland, which does not make enough 
thyroid hormone because of insufficient thyroid stimulating hormone 
(TSH) from the pituitary. Babies born like this have congenital 
hypothyroidism (CHT). By measuring thyroid hormone levels in all 
babies shortly after birth, newborn screening programmes are able to 
identify infants with low thyroid hormone levels who may have CHT 
before there are any signs or symptoms of hypothyroidism. Prompt and 
appropriate treatment of infants with CHT with manufactured thyroid 
hormone (thyroxine) allows normal growth and intellectual development. 
CHT has been screened for throughout the UK since the 1980s. 
 
confirmed result A confirmed result is used to refer to a positive screening result that 
has been confirmed by further diagnostic tests. Screening test results 
are often called presumptive results.  Screening tests are not 
diagnostic tests; abnormal screening results need to be followed by 
further testing.  A confirmed result could be a normal result, meaning 
that the individual is found to be unaffected by any of the conditions 
screened for. 
 
consent Consent is agreement to a plan of action or particular treatment. 
“Informed consent” is when a patient (or parent) is given information and 
then voluntarily agrees to continue. Another term used is “informed 
choice”. Informed choice is when a patient (or parent) is given a choice 
and provided with information about the procedure, treatment or test to 
inform their decision.  
 
coverage When assessing screening programmes, one term used is coverage. 
This term describes the proportion of people eligible for screening who 
are actually screened. The success of screening programmes is 
sometimes measured by the coverage achieved.  Within the newborn 
bloodspot screening programme, very high levels of coverage have 
been recorded in the UK but we need to continue to record this 
information to identify any problems at an early stage.  
 
cystic fibrosis Cystic fibrosis (CF) is a condition that affects the organs in the body, 
especially the lungs and pancreas, by clogging them with thick sticky 
mucus. Children who have cystic fibrosis are born with the disorder, but 
early recognition of the diagnosis may be delayed by either lack of 
symptoms or failure to recognise that symptoms may be due to CF. 
Hence newborn screening can help make the diagnosis earlier for some 
families allowing earlier access to treatment.   There is no cure for cystic 
fibrosis, but early treatment appears to improve the health of affected 
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children. Cystic fibrosis is more common in some populations within the 
UK than others. Some areas have been screening for CF in the UK 
since the 1980s and more recently, newborn screening for CF has 
started in Scotland. Within the next few years all newborn babies born in 
the UK will be screened for cystic fibrosis. 
 
diagnosis / diagnostic 
test 
A diagnostic test is one which tests for a specific condition, and 
confirms whether or not someone has a condition. Several diagnostic 
tests may follow a positive screening result in order to obtain a 
confirmed result. For example a newborn baby might be screened for 
CHT and the screening result is positive.  Further diagnostic tests will 
then be carried out to find out whether the child definitely has 
CHT.  However, treatment will often be started before the confirmed 
result is available, as this may take some weeks. 
 
disease Different words are used to describe illnesses. They are sometimes 
called diseases, or disorders, or conditions. 
 
disorder Different words are used to describe illnesses. They are sometimes 
called diseases, or disorders, or conditions. 
 
false-negative A child with a false-negative screening result is one who really has the 
disorder even though the screening result was negative. For example, a 
child who has a false-negative result for CHT is one who is told that 
they don’t have the condition, and then it turns out that they do have 
CHT. Depending on the condition, this can be very serious. All 
screening tests are associated with a variable risk of false- negative and 
false-positive results. 
 
false-positive A child with a false-positive screening result is one who is thought to 
have the disorder when in fact they do not.   For example, a child who 
has a false-positive result for CHT is a child who has been told they 
have the condition, and then it turns out that this is not the case. For 
parents, receiving a false-positive result can mean that they think that 
their child is sick, when actually their child is healthy. 
 
Guthrie Card When the midwife collects small drops of blood from a newborn baby, 
she puts them on a special piece of filter paper, which is often referred 
to as a Guthrie Card. This special card, named after Dr Robert Guthrie 
who developed a simple accurate test for PKU in 1963, allows the blood 
to be stored as blood spots on the card while it is sent to the laboratory 
for testing. 
 
haemoglobinopathies Haemoglobinopathies are disorders of haemoglobin. Haemoglobin is 
the part of our blood that carries oxygen. There a large number of 
different haemoglobinopathies, some are more serious than others. 
Sickle cell disease is a haemoglobinopathy as is thalassaemia. 
Haemoglobinopathies are more common in some populations within the 
UK than others. Haemoglobinopathies can be tested for in pregnant 
mothers, and unborn babies, as well as newborn babies. In the UK 
some areas have been screening newborn babies for sickle cell 
disorders since the 1980s. In many areas only those babies thought to 
be at high risk are tested. This is changing and over the next few years 
all newborn babies in England will be screened for sickle cell 
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disorders. 
 
heterozygote A heterozygote is another term for a carrier. A carrier has a single 
copy of a change or mutation in a particular gene pair when, for that 
gene pair, disease only results when both copies have a mutation.  The 
carrier can pass on the changed gene to their offspring.  A distinction is 
made between a simple heterozygote, a person who carries only one 
copy of a genetic mutation and is therefore unaffected by a disease (e.g.
sickle cell trait) and a compound heterozygote, who carries two 
different genetic mutations and is affected by the disorder (sickle cell 
disease).  
 
informatics Health informatics is an evolving scientific discipline that deals with the 
responsible collection, storage, retrieval, communication and optimal 
use of health related data, information and knowledge. to improve 
patient care, medical education, and health sciences research. 
 
negative screening 
result 
A negative screening result suggests that it is unlikely that the child 
has a disease. Under these circumstances further diagnostic tests are 
not needed to show whether or not the child is in fact affected by the 
condition screened for.  A negative result is sometimes referred to as a 
normal result.  This is a misleading term, however, as screening is not 
100% certain and a child with a negative screening result may later turn 
out to have the disease, while conversely, a child with a positive result 
may turn out not to have the condition.  
 
neonatal screening Neonatal screening can also be called newborn screening. All 
screening on a newborn baby is called neonatal (or newborn) 
screening. There are different newborn screening tests, for example 
neonatal screening includes hearing screening, hips screening and 
bloodspot screening.  
 
normal (result) Sometimes when the result of the test shows that the child does not 
have (or is unlikely to have) the condition tested for, people say the 
result is normal. In general it is best to avoid using this term, as it is not 
always clear what normal is meant to be. It is a misleading term to refer 
to in screening results as screening is not 100% certain and a child with 
a negative screening result may later turn out to have the disease, 
while conversely, a child with a positive screening result may turn out 
not to have the condition 
 
notification When talking about screening people often refer to notification of results. 
This can mean a number of slightly different things. Sometimes 
notification means the reporting of a screening result to a register, or a 
health monitoring group, such as the child health record. Sometimes 
notification refers to telling parents or patients the results of their tests. 
When talking about notification, it is important to be clear about what 
information is being notified, and who is being notified about this 
information. 
 
Personal Child Health 
Record (PCHR)  
The Personal Child Health Record is the child health record held by 
the parent. It is a book normally issued by the health visitor at 10 days of 
age, or sometimes sooner.  The PCHR contains information about the 
child’s health, such as dates of vaccinations 
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positive result A positive screening result suggests that it is more likely that the child 
has a disease. A positive screening result indicates that further 
diagnostic tests are needed to show whether or not the child is in fact 
affected by the condition screened for.  A child cannot be said to be 
affected until further diagnostic tests are undertaken and a confirmed 
result is obtained 
 
presumptive screening 
results 
Presumptive screening results are results which are not yet 
confirmed, but which are considered highly likely. A presumptive positive 
for CHT means that it is very likely, or assumed that the child has CHT. 
This result is then confirmed using a diagnostic test. Screening results 
are described as presumptive. A presumptive positive result can also be 
described as a positive screening result or screen positive. A 
presumptive negative result can also be described as a negative 
screening result, or screen negative.  
  
process standards Agreed standards that should be achieved at each stage of the 
screening process: informing parents, taking the sample, laboratory 
testing, informing clinicians and parents of the results, and starting 
treatment of affected newborns as soon as it is beneficial. 
 
quality assurance Quality assurance is a system for monitoring and maintaining high 
standards in every aspect of the screening programme. 
 
registers / disease 
registers 
There are a number of disease registers in the UK, which keep a 
record of the number of people with particular conditions. These 
registers can serve different purposes: ensuring people with the 
condition are followed up, and treated and helping us to understand 
more about these conditions and how they affect people etc. There are 
different registers which collect slightly different information about 
different conditions. One of the tasks of the Programme Centre is to 
develop and maintain national registers for conditions which are 
screened for in newborn blood spot screening. 
 
screen negative (results) Screening results are not 100% conclusive. Instead they provide 
presumptive results, which are then confirmed using diagnostic tests.
A screen negative result for CHT, means that it is highly likely that the 
child does NOT have CHT. This screen negative result is NOT usually 
confirmed using further tests, but it is assumed the child is not affected. 
 
screen positive (results) Screening results are not 100% conclusive. Instead they provide 
presumptive results, which are then confirmed using diagnostic tests. 
A screen positive result for CHT, means that it is highly likely that the 
child has CHT, but that this must still be confirmed by further tests. 
 
screening Screening is when healthy children and adults are tested to see if they 
are likely to develop a condition. Screening tests don't generally confirm 
that a person has a disease. Usually they will not feel ill from these 
conditions in any way at the time when they're screened. Screening 
allows diseases to be identified early, before any signs of illness. This 
means people can be treated quickly, and hopefully avoid getting 
seriously ill. Screening can happen at different stages, and for different 
conditions. Newborn screening in this country includes tests for 
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phenylketonuria (PKU), congenital hypothyroidism (CHT), cystic 
fibrosis (CF), and sickle cell disorders. 
 
sensitivity The sensitivity of a screening test refers to the proportion of 
individuals who have the condition who are correctly identified by the 
screening test.  A highly sensitive test may identify nearly all those 
affected, i.e. it has a sensitivity approaching 100%.  The consequence of 
a test that lacks sensitivity is that individuals with a negative screening 
result may believe they do not have the disease when in fact they 
do.  They have a false-negative screening result and are falsely 
reassured by the screen.  
 
setting standards Setting standards is the process by which minimum acceptable 
standards, achievable standards and optimal standards are agreed. This 
is usually through discussion and review of current practice and 
research by clinicians, managers, researchers and, increasingly, people 
using the services 
 
sickle cell disorders Sickle Cell disorders (also known as sickle cell disease) are a group 
of conditions that affect the way that our blood carries oxygen. The part 
of the blood that carries oxygen is called haemoglobin, which is found 
inside our red blood cells. Sickle Cell disorders can also be called 
haemoglobin-opathies.   Types of sickle cell disorders include sickle 
cell anaemia, haemoglobin SC disease and sickle beta thalassaemia.  A 
person who has a sickle cell disorder has red blood cells which, under 
certain conditions, change their shape to that resembling a sickle or half-
moon. These cells cannot carry oxygen properly. The condition can be 
very painful and can cause various health problems including anaemia, 
episodes of pain, strokes, and life-threatening infections. Treatment with 
penicillin may prevent serious infections in early childhood. 
 
specificity The specificity of a screening test refers to the proportion of 
individuals who do not have the disease who are correctly identified by 
the screen.  A highly specific test means that all those who are not 
affected are correctly identified, i.e. the specificity approaches 
100%.  The consequence of a test that lacks specificity is that an 
individual may receive a false-positive result, indicating that they may 
have a condition when in fact they do not. 
true-negative A true-negative result is one which is thought to be negative and is. A 
person with a true negative result for CHT, is someone who does not 
have CHT. 
 
true-positive A true-positive result is one which is thought to be positive and is. A 
person with a true positive result for a condition, is someone who has 
that condition. 
 
UK The UK includes England, Wales, Scotland and Northern Ireland. 
 
UK Newborn Screening 
Programme Centre 
The UK Newborn Screening Programme Centre has been funded by 
the Department of Health to develop national standards for newborn 
bloodspot screening. The Programme Centre is  made up of a team of 
people from  Great Ormond Street Hospital NHS Trust, the Institute of 
Child Health and the Institute of Education. 
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Working Group A working group is a group of people who meet on several occasions 
to complete a particular task.  For example, a working group may be 
convened to decide the standards for newborn screening services 
(Process Standards Working Group), or to prepare parent information 
on newborn screening (Information and Communication Working 
Group).  
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